Stryker (SYK) 10-K 11 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Jan. 31, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	SYK
Entity Registrant Name	STRYKER CORP
Entity Central Index Key	310,764
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		372,982,213
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 33,330,554,534

Consolidated Statements Of Earn

Consolidated Statements Of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales	$ 9,946	$ 9,675	$ 9,021
Cost of sales	3,344	3,319	3,002
Gross profit	6,602	6,356	6,019
Research, development and engineering expenses	625	614	536
Selling, general and administrative expenses	3,610	3,547	3,467
Recall charges, net of insurance proceeds	296	761	622
Intangible asset amortization	210	188	138
Total operating expenses	4,741	5,110	4,763
Operating income	1,861	1,246	1,256
Other income (expense), net	(126)	(86)	(44)
Earnings before income taxes	1,735	1,160	1,212
Income taxes	296	645	206
Net earnings	$ 1,439	$ 515	$ 1,006
Net earnings per share of common stock:
Basic net earnings per share of common stock (in dollars per share)	$ 3.82	$ 1.36	$ 2.66
Diluted net earnings per share of common stock (in dollars per share)	$ 3.78	$ 1.34	$ 2.63
Weighted-average shares outstanding - in millions:
Basic (in shares)	376.6	378.5	378.6
Net effect of dilutive employee stock options (in shares)	4.3	4.3	3.5
Diluted (in shares)	380.9	382.8	382.1
Anti-dilutive shares excluded from the calculation of net effect of dilutive employee stock options (in shares)	0	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,439	$ 515	$ 1,006
Other comprehensive income, net of tax
Marketable securities	(3)	3	(4)
Pension plans	17	(55)	20
Unrealized (losses) gains on designated hedges	(9)	6	7
Financial statement translation	(390)	(440)	80
Total other comprehensive (loss) income, net of tax	(385)	(486)	103
Comprehensive income	$ 1,054	$ 29	$ 1,109

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 3,379	$ 1,795
Marketable securities	700	3,205
Accounts receivable, less allowance of $61 ($59 in 2014)	1,662	1,572
Inventories
Materials and supplies	304	248
Work in Process	103	88
Finished Goods	1,232	1,252
Total inventories	1,639	1,588
Prepaid expenses and other current assets	564	524
Total current assets	7,944	8,684
Property, plant and equipment
Land, buildings and improvements	687	678
Machinery and equipment	2,043	1,919
Total property, plant and equipment	2,730	2,597
Less allowance for depreciation	1,531	1,499
Net property, plant and equipment	1,199	1,098
Other assets
Goodwill	4,136	4,186
Other intangibles, net	1,794	2,018
Other noncurrent assets	1,174	1,293
Total assets	16,247	17,279
Current liabilities
Accounts payable	410	329
Accrued compensation	637	597
Income taxes	141	333
Dividend payable	142	131
Accrued recall expenses	694	1,593
Accrued expenses and other liabilities	710	751
Current maturities of debt	769	727
Total current liabilities	3,503	4,461
Long-term debt, excluding current maturities	3,253	3,246
Other noncurrent liabilities	980	977
Shareholders' equity
Common stock, $0.10 par value: Authorized: 1 billion shares, Outstanding: 378 million shares (378 million in 2013)	37	38
Additional paid-in capital	1,321	1,252
Retained earnings	7,792	7,559
Accumulated other comprehensive income	(639)	(254)
Total shareholders' equity	8,511	8,595
Total liabilities & shareholders' equity	$ 16,247	$ 17,279

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 61	$ 59
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, outstanding (in shares)	373,000,000	378,000,000

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period at Dec. 31, 2012	$ 8,597	$ 38	$ 1,098	$ 7,332	$ 129
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	1,006			1,006
Other comprehensive income	103				103
Issuance of shares of common stock under stock option and benefit plans, including excess income tax benefit	(1)		(1)
Repurchase and retirement of shares of common stock	(317)		(13)	(304)
Share-based compensation	76		76
Cash dividends declared of common stock	(417)			(417)
Balance at end of period at Dec. 31, 2013	9,047	38	1,160	7,617	232
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	515			515
Other comprehensive income	(486)				(486)
Issuance of shares of common stock under stock option and benefit plans, including excess income tax benefit	19		19
Repurchase and retirement of shares of common stock	(100)		(4)	(96)
Share-based compensation	77		77
Cash dividends declared of common stock	(477)			(477)
Balance at end of period at Dec. 31, 2014	8,595	38	1,252	7,559	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	1,439
Other comprehensive income	(385)
Issuance of shares of common stock under stock option and benefit plans, including excess income tax benefit	8		8
Repurchase and retirement of shares of common stock	(700)	(1)	(25)	(674)
Share-based compensation	86		86
Cash dividends declared of common stock	(532)			(532)
Balance at end of period at Dec. 31, 2015	$ 8,511	$ 37	$ 1,321	$ 7,792	$ (639)

Consolidated Statements Of Sha7

Consolidated Statements Of Shareholders' Equity (Parenthetical) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Stockholders' Equity [Abstract]
Issuance of common stock under stock option and benefit plans, shares	1.8	2.2	2.1
Issuance of common stock under stock option and benefit plans, excess income tax benefit	$ 26	$ 21	$ 6
Repurchase and retirement of common stock, shares	7.4	1.3	4.8
Cash dividends declared, per share of common stock	$ 1.415	$ 1.26	$ 1.10

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net earnings	$ 1,439	$ 515	$ 1,006
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	187	190	169
Amortization of intangible assets	210	188	138
Share-based compensation	86	77	76
Gross recall charges	349	940	622
Sale of inventory stepped up to fair value at acquisition	7	27	28
Deferred income tax benefit	87	60	23
Changes in operating assets and liabilities:
Accounts receivable	(151)	(89)	(89)
Inventories	(115)	(173)	(77)
Accounts payable	35	13	1
Accrued expenses and other liabilities	73	92	41
Recall-related payments	(1,206)	(98)	(6)
Income taxes	(290)	133	(124)
Other	188	(93)	78
Net cash provided by operating activities	899	1,782	1,886
Investing activities
Acquisitions, net of cash acquired	(153)	(916)	(2,320)
Purchases of marketable securities	(1,715)	(4,365)	(4,558)
Proceeds from sales of marketable securities	4,094	3,636	4,856
Purchases of property, plant and equipment	(270)	(233)	(195)
Net cash provided by (used in) investing activities	1,956	(1,878)	(2,217)
Financing activities
Proceeds from borrowings	1,576	1,601	369
Payments on borrowings	(2,272)	(1,428)	(355)
Proceeds from issuance of long-term debt, net	744	986	991
Dividends paid	(521)	(462)	(401)
Repurchase of common stock	(700)	(100)	(317)
Other financing	32	32	13
Net cash (used in) provided by financing activities	(1,141)	629	300
Effect of exchange rate changes on cash and cash equivalents	(130)	(77)	(25)
Change in cash and cash equivalents	1,584	456	(56)
Cash and cash equivalents at beginning of year	1,795	1,339	1,395
Cash and cash equivalents at end of year	3,379	1,795	1,339
Supplemental cash flow disclosure:
Cash paid for income taxes, net of refunds	497	437	321
Cash paid for interest on debt	$ 101	$ 102	$ 88

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	SIGNIFICANT ACCOUNTING POLICIES Nature of Operations: Stryker Corporation (the "Company," "we," "us," or "our") is a global leader in medical technology. Our products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties. Basis of Presentation and Consolidation: The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Certain prior year amounts have been reclassified to conform with the presentation of our Consolidated Financial Statements and in Note 13 for 2015. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition: Sales are recognized when revenue is realized or realizable and has been earned. Our policy is to recognize revenue when title to the product, ownership and risk of loss transfer to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most orthopaedics products, when we receive appropriate notification that the product has been used or implanted. A provision for estimated sales returns, discounts, rebates and other sales incentives is recorded as a reduction of net sales in the same period that the revenue is recognized. Shipping and handling costs charged to customers are included in net sales. Cost of Sales: Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity. Research, Development and Engineering Expenses: Research and development costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. Selling, General and Administrative Expenses: Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items. Currency Translation: Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in earnings. Cash Equivalents: Highly liquid investments with remaining stated maturities of three months or less when purchased are considered cash equivalents and recorded at cost. Marketable Securities: Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Accounts Receivable: Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience and expected future trends. Accounts receivable are written off when all reasonable collection efforts are exhausted. Inventories: Inventories are stated at the lower of cost or market, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to market prices. Financial Instruments: Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. With the exception of our long-term debt, which is discussed in further detail in Note 9, our estimates of fair value for financial instruments approximate their carrying amounts on December 31, 2015 and 2014 . All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recorded in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and loses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method. We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is an other-than-temporary impairment. The resulting losses from other-than-temporary impairments of available-for-sale marketable securities are included in earnings. Derivatives: All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. These nonfunctional currency exposures principally relate to intercompany receivables and payables arising from intercompany purchases of manufactured products. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period, with resulting gains (losses) included in earnings. Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the consolidated balance sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in other income (expense), net or cost of goods sold in the consolidated statements of earnings, depending on the underlying transaction that is being hedged. We report our derivative instruments on a gross basis. Interest rate derivative instruments designated as fair value hedges are being used to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. For derivative instruments designated as net investment hedges of our foreign operations, the gain or loss is recorded in the cumulative translation adjustment within AOCI together with the offsetting loss or gain of the hedged exposure of the underlying foreign operations. Any ineffective portion of the net investment hedges is reported in earnings during the period of change. Hedge effectiveness for equity forward contracts and foreign exchange net investment hedge forward contracts is assessed by comparing changes in fair value due to changes in spot rates for both the derivative and the hedged item. Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to ten years for machinery and equipment. Goodwill and Other Intangible Assets: Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase revenues and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. The fair values of other identifiable intangible assets are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below. In certain of our acquisitions, we acquire in-process research and development (IPRD) which are indefinite-lived intangible assets. IPRD where research has been completed becomes a determinable-lived intangible asset and IPRD determined to have no future use becomes impaired. Goodwill, Intangibles and Long-Lived Asset Impairment Tests: We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value. We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell. Share-Based Compensation: We use share based compensation in the form of stock options, restricted stock units (RSUs) and performance-based restricted stock units (PSUs). Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized to date associated with grants that are not expected to vest will be reversed. Income Taxes: Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities during the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate. We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates. New Accounting Pronouncements Not Yet Adopted In April 2015 the FASB issued ASU 2015-03, Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update requires an entity to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability consistent with debt discounts and is effective for financial statements issued for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. We adopted this standard on January 1, 2016 and do not expect it to have a material impact on the Consolidated Financial Statements. In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This guidance, which is effective for financial statements issued for fiscal years beginning after December 15, 2017, outlines a single, comprehensive model for accounting for revenue from contracts with customers. We plan to adopt this standard on January 1, 2018. We are still evaluating what impact, if any, that the standard will have on our financial statements.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENT On February 1, 2016 we entered into a definitive agreement to acquire Sage Products, LLC (Sage) in an all cash transaction for $ 2,775 . Sage develops, manufactures and distributes disposable products targeted at reducing "Never Events," primarily in the intensive care unit and MedSurg hospital unit setting. Sage’s products include solutions for oral care, skin preparation and protection, patient cleaning and hygiene, turning and positioning devices and heel care boots. This transaction is expected to close during the second quarter of 2016.

Changes in Accumulated Other Co

Changes in Accumulated Other Comprehensive Income Changes in Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2015
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]
Changes in Accumulated Other Comprehensive Income	CHANGES IN ACCUMULATED OTHER COMPREHENSIVE INCOME 2015 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ 3 $ (136 ) $ 13 $ (134 ) $ (254 ) OCI before reclassifications 1 15 2 (362 ) (344 ) Tax (benefit) expense on OCI (1 ) (4 ) 2 (28 ) (31 ) Reclassifications out of AOCI, net Cost of Sales — 8 (19 ) — (11 ) Other (income) expense (4 ) — — — (4 ) Income tax expense (benefit) 1 (2 ) 6 — 5 Net current period OCI $ (3 ) $ 17 $ (9 ) $ (390 ) $ (385 ) Ending $ — $ (119 ) $ 4 $ (524 ) $ (639 ) 2014 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (81 ) $ 7 $ 306 $ 232 OCI before reclassifications 12 (72 ) 10 (440 ) (490 ) Tax (benefit) expense on OCI (2 ) 22 (4 ) — 16 Reclassifications out of AOCI, net Cost of Sales — (6 ) (1 ) — (7 ) Other (income) expense (9 ) — — — (9 ) Income tax expense (benefit) 2 1 1 — 4 Net current period OCI $ 3 $ (55 ) $ 6 $ (440 ) $ (486 ) Ending $ 3 $ (136 ) $ 13 $ (134 ) $ (254 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 2 Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3 Unobservable inputs reflecting our assumptions or external inputs from active markets. When applying fair value principles in the valuation of assets and liabilities, we are required to maximize the use of quoted market prices and minimize the use of unobservable inputs. We calculate the fair value of our Level 1 and Level 2 instruments based on the exchange traded price of similar or identical instruments, where available, or based on other observable inputs taking into account our credit risk and that of our counterparties. Foreign currency exchange contracts and interest rate hedges are included in Level 2 as we use inputs other than quoted prices that are observable for the asset or liability. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Our Level 3 liabilities represent milestone payments for acquisitions. The fair value of the liability was estimated using a discounted cash flow technique. Significant unobservable inputs to this technique included our probability assessments of occurrence of triggering events, appropriately discounted considering the uncertainties associated with the obligation. We remeasure our assets and liabilities each reporting period and record the changes in fair value within selling, general and administrative expense and the changes in the time value of money within other income (expense), net. 2015 2014 Cash and cash equivalents $ 3,379 $ 1,795 Trading marketable securities 82 80 Level 1 - Assets $ 3,461 $ 1,875 Available-for-sale marketable securities Corporate and asset-backed debt securities $ 214 $ 1,525 Foreign government debt securities 96 726 United States agency debt securities 120 382 United States treasury debt securities 264 474 Certificates of deposit 8 110 Other — 12 Total available-for-sale marketable securities $ 702 $ 3,229 Foreign currency exchange forward contracts 69 32 Interest rate swap asset 15 10 Level 2 - Assets $ 786 $ 3,271 Total assets measured at fair value $ 4,247 $ 5,146 Deferred compensation arrangements $ 82 $ 80 Level 1 - Liabilities $ 82 $ 80 Foreign currency exchange forward contracts $ 10 $ 12 Interest rate swap liability 4 — Level 2 - Liabilities $ 14 $ 12 Contingent consideration Beginning balance $ 48 $ 59 Additions 11 — Losses included in earnings — 4 Settlements (3 ) (15 ) Balance at the end of the period $ 56 $ 48 Level 3 - Liabilities $ 56 $ 48 Total liabilities measured at fair value $ 152 $ 140 Fair Value of Available for Sale Securities by Contractual Maturity 2015 2014 Due in one year or less $ 588 $ 430 Due after one year through three years $ 114 $ 2,505 Due after three years $ — $ 294 On December 31, 2015 the aggregate difference between the cost and fair value of available-for-sale marketable securities is not material. Interest receivable of $ 2 related to our marketable securities portfolio was recorded in prepaid expenses and other current assets. While some investments have been downgraded by rating agencies since their initial purchase, less than 1% of our investments in available-for-sale marketable securities had a credit quality rating of less than A2 (Moody's), A (Standard & Poors) and A (Fitch). We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity, we do not consider these investments to have other-than-temporarily impairment on December 31, 2015 . Securities in a Continuous Unrealized Loss Position Number of Investments Fair Value Corporate and Asset-Backed 98 $ 117 Foreign Government 10 30 United States Agency 8 18 United States Debt 15 38 Certificate of Deposit 6 4 Total 137 $ 207 On December 31, 2015 substantially all our investments with unrealized losses that are not deemed to be other-than-temporarily impaired have been in a continuous unrealized loss position for less than twelve months and the losses are not considered material. The total of interest and marketable securities income was $ 14 , $ 28 , and $ 24 in 2015 , 2014 , and 2013 . The amounts are included in other income (expense), net.

Derivative Instruments

Derivative Instruments	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings and cash flow. At the inception, the derivative is designated as a cash flow hedge, fair value hedge or is a free standing derivative. We do not enter into derivative instruments for speculative purposes. Non-designated Foreign Exchange Forward Contract Derivatives Derivative forward contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the measurement of the contracts at month-end spot rates as adjusted by current forward points. Designated Foreign Exchange Forward Contract Derivatives We use a layered hedging program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. These foreign exchange contracts generally have maturities up to eighteen months. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of AOCI and reclassified into other income (expense), net or cost of sales within earnings in the same period during which the hedged transaction affects earnings. Cash flows associated with these hedges are included in cash from operations in the same category as the cash flows from the items being hedged. Designated Net Investment Hedges We have designated certain long-term intercompany loans payable and forward exchange contracts as net investment hedges of our investments in certain international subsidiaries that use the Euro as their functional currency. The effective portion of derivatives designated as net investment hedges are recorded at fair value at each balance sheet date and the change in fair value is recorded as a component of AOCI. On December 31, 2015 the total after-tax amount in AOCI related to our designated net investment hedges was $ 21 . For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is reported as a component of OCI and recorded in AOCI. We use the forward method to measure ineffectiveness. Under this method, for each reporting period, the change in the carrying value of the Euro-denominated amounts due to remeasurement of the effective portion is reported as a component of AOCI and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income (expense), net. The gain or loss related to settled net investment hedges will be subsequently reclassified into net earnings when the hedged net investment is either sold or substantially liquidated. We evaluate the effectiveness of our net investment hedges quarterly and did not record any ineffectiveness in 2015. Designated Non-Designated Total 2015 Gross notional amount $ 889 $ 4,061 $ 4,950 Maximum term in days 546 Fair value: Other current assets $ 27 $ 41 $ 68 Other noncurrent assets 1 — 1 Other current liabilities (6 ) (3 ) (9 ) Other noncurrent liabilities (1 ) — (1 ) Total fair value $ 21 $ 38 $ 59 2014 Gross notional amount $ 357 $ 2,085 $ 2,442 Maximum term in days 546 Fair value: Other current assets $ 18 $ 12 $ 30 Other noncurrent assets 2 — 2 Other current liabilities — (12 ) (12 ) Total fair value $ 20 $ — $ 20 We are exposed to credit loss in the event of nonperformance by counterparties on our outstanding forward currency exchange contracts but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. Net Currency Exchange Rate Gains (Losses) Recorded in: 2015 2014 2013 Cost of sales $ 19 $ 1 $ — Other income (expense), net (22 ) (8 ) 3 Total $ (3 ) $ (7 ) $ 3 On December 31, 2015 and 2014 pretax gains on derivatives designated as hedges of $17 and $ 15 , which are recorded in AOCI, are expected to be reclassified to earnings during the next 12 months. This reclassification is primarily due to the sale of inventory that includes previously hedged purchases. There have been no ineffective portions of derivatives that have resulted in gains or losses in any of the periods presented. Interest Rate Risk on Future Debt Issuance Forward starting interest rate derivative instruments designated as cash flow hedges are used to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. The effective portion of the gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges is reported as a component of AOCI. Beginning in the period in which the debt refinancing occurs and the related derivative instruments is terminated, the effective portion of the gains or losses is then reclassified into interest expense over the term of the related debt. On December 31, 2015 we had interest rate swaps with notional amounts of $ 375 designated as forward starting interest rate swaps in anticipation of future debt issuances. The market value of outstanding interest rate swap agreements on December 31, 2015 was $ 4 , which is recorded in accrued expenses and other liabilities with an offsetting amount recorded in AOCI. Upon the probable issuance of the debt, these amounts will be released to interest expense over the term of the debt. The cash flow effect of this hedge is recorded in cash flow from operations. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are used to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. On December 31, 2015 we had interest rate swaps in gross notional amounts of $500 designated as fair value hedges of underlying fixed rate obligations representing a portion of our $600 senior unsecured notes due in 2024. There was no hedge ineffectiveness recorded as a result of these fair value hedges. Fair Value Interest Rate Hedge Instruments 2015 2014 Gross notional amount $ 500 $ 500 Fair value: Other noncurrent assets 15 10 Long-term debt (15 ) (10 ) Total fair value $ — $ — We are exposed to credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS 2015 Acquisitions In January 2015 we acquired certain assets of CHG Hospital Beds, Inc. (CHG). CHG designs, manufactures and markets low-height hospital beds and related accessories. This acquisition enhances our product offerings within our MedSurg segment and is included in the 2015 Other column in the table below. Goodwill acquired associated with the CHG acquisition is deductible for tax purposes. 2014 Acquisitions In September 2014 we acquired certain assets of Small Bone Innovations, Inc. (SBi) for an aggregate purchase price of $365 . SBi products are designed and promoted for upper and lower extremity small bone indications, with a focus on small joint replacement. The acquisition of the assets of SBi enhances our product offerings within our Orthopaedics segment. Goodwill acquired associated with the SBi acquisition is deductible for tax purposes. In April 2014 we acquired Berchtold Holding, AG (Berchtold) for an aggregate purchase price of $184 . Berchtold sells surgical tables, equipment booms and surgical lighting systems. In March 2014 we acquired Patient Safety Technologies, Inc. (PST), for an aggregate purchase price of $120 . PST’s proprietary Safety-Sponge ® System and SurgiCount 360™ compliance software help prevent Retained Foreign Objects in the operating room. In addition the acquisition of Pivot Medical Inc. which develops and sells innovative products for hip arthroscopy and other 2014 acquisitions are included in the 2014 Other column in the table below. These acquisitions enhance our product offerings within our MedSurg segment. The measurement periods for our acquisitions in 2014 have been completed. Revisions to the original purchase price allocation were not material. The purchase price allocations for the 2015 acquisitions were based upon preliminary valuations, and our estimates and assumptions are subject to change within the measurement period. On December 31, 2015 management is in the process of verifying data and finalizing information related to the 2015 acquisitions and the valuation and recording of identifiable intangible assets, deferred income taxes and the corresponding effect on the value of goodwill. Purchase Price Allocation of Acquired Net Assets 2015 2014 Other SBi Berchtold PST Other Purchase price paid $ 138 $ 365 $ 184 $ 120 $ 216 Contingent consideration 9 — — — — Total consideration $ 147 $ 365 $ 184 $ 120 $ 216 Tangible assets acquired: Cash — — 12 — — Inventory 10 23 22 7 5 Other assets 17 6 44 19 25 Liabilities (5 ) (2 ) (45 ) (31 ) (29 ) Intangible assets: Customer relationship 12 20 11 33 5 Trade name 2 — 7 — — Developed technology and patents 51 73 32 26 115 Other 2 1 — — — IPRD — 1 — — 2 Goodwill 58 243 101 66 93 $ 147 $ 365 $ 184 $ 120 $ 216 Weighted average life of intangible assets 10 12 8 14 12

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	GOODWILL AND OTHER INTANGIBLE ASSETS We completed our annual impairment tests of goodwill in 2015 and 2014 and concluded in each year that no impairments exist. Summary of Other Intangible Assets Weighted Average Amortization Period (Years) Gross Less Net Developed technologies 2015 13 $ 1,597 $ 563 $ 1,034 2014 13 1,468 466 1,002 Customer relationships 2015 15 $ 788 $ 290 $ 498 2014 15 801 239 562 Patents 2015 11 $ 309 $ 191 $ 118 2014 12 293 175 118 Trademarks 2015 10 $ 109 $ 41 $ 68 2014 14 112 37 75 In-process research and development 2015 $ 25 $ — $ 25 2014 201 — 201 Other 2015 13 $ 108 $ 57 $ 51 2014 12 111 51 60 Total 2015 13 $ 2,936 $ 1,142 $ 1,794 2014 13 $ 2,986 $ 968 $ 2,018 Changes in the Net Carrying Value of Goodwill by Segment Orthopaedics MedSurg Neurotechnology and Spine Total 2013 $ 2,227 $ 506 $ 1,111 $ 3,844 Additions and adjustments 186 231 23 440 Foreign exchange (27 ) (11 ) (60 ) (98 ) 2014 $ 2,386 $ 726 $ 1,074 $ 4,186 Additions and adjustments 20 46 — 66 Foreign exchange (62 ) 10 (64 ) (116 ) 2015 $ 2,344 $ 782 $ 1,010 $ 4,136 Amortization expense related to intangible assets was $ 210 , $ 188 and $ 138 for 2015 , 2014 and 2013 . Estimated Amortization Expense 2016 2017 2018 2019 2020 $ 202 $ 183 $ 181 $ 165 $ 148 During 2015 we placed certain in process research and development assets into service as a result of the Food and Drug Administration's (FDA) clearance of our Mako total knee application.

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	CONTINGENCIES AND COMMITMENTS We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters that are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management has sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for product liability-related claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. On November 3, 2014 we announced that we had entered into a settlement agreement to compensate eligible United States patients who had revision surgery to replace their Rejuvenate and/or ABG II Modular-Neck hip stem prior to that date. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, some lawsuits will remain and we will continue to defend against them. Based on the information that has been received, the actuarially determined range of probable loss to resolve this matter globally is estimated to be approximately $ 1,824 ($ 2,056 before $ 232 of third-party insurance recoveries) to $ 2,416 . In 2015 we recorded additional charges to earnings of $ 295 , net of insurance recoveries, representing the excess of the minimum of the range over the previously recorded reserves. In 2015 we made recall-related payments totaling $ 1,202 under the United States Rejuvenate and ABG II settlement agreement. The final outcome of this matter is dependent on many factors that are difficult to predict including the number of enrollees in the settlement program and the total awards to them, the number and costs of patients not eligible for the settlement program who seek testing and treatment services and require revision surgery and the number and actual costs to resolve the remaining lawsuits. Accordingly, the ultimate cost to resolve this entire matter globally may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. In 2010 we filed a lawsuit in federal court against Zimmer Biomet Holdings, Inc. (Zimmer), alleging that a Zimmer product infringed three of our patents. In 2013 following a jury trial favorable to us, the trial judge entered a final judgment that, among other things, awarded us damages of $ 76 and ordered Zimmer to pay us enhanced damages. Zimmer appealed this ruling. In December 2014 the Federal Circuit affirmed the damages awarded to us, reversed the order for enhanced damages and remanded the issue of attorney fees to the trial court. The Federal Circuit denied our petition for a rehearing en banc on the issue of enhanced damages but on October 19, 2015 the United States Supreme Court agreed to hear our appeal on this issue. In May 2015 the trial court entered a stipulated final judgment that, among other things, required Zimmer to pay us the base amount of damages and interest, while the issues of enhanced damages and attorney fees continue to be pursued. In 2015 we received payment of $ 54 , net of legal costs, which has been recorded within selling, general and administrative expenses. In April 2011 Hill-Rom Company, Inc. and affiliated entities (Hill-Rom) brought a lawsuit against us alleging infringement under United States patent laws with respect to nine patents related to electrical network communications for hospital beds. On March 31, 2015 the court granted the parties’ joint motion to dismiss with prejudice the claims and counterclaims associated with three of these patents. The case has been stayed with respect to the remaining six patents, which currently are under reexamination by the United States Patent Office. The ultimate resolution of this matter cannot be predicted and it is not possible at this time for us to estimate any probable loss or range of probable losses; however, the ultimate result could have a material adverse effect on our financial position, results of operations and cash flows. Purchase Commitments and Operating Leases We have purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. In addition, we lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. Rent expense totaled $ 101 , $103 , and $100 in 2015 , 2014 and 2013 . Future Commitments under Purchase Obligations and Leases 2016 2017 2018 2019 2020 Thereafter Purchase obligations $ 802 $ 125 $ 62 $ 55 $ 2 $ 67 Minimum lease payments $ 69 $ 51 $ 39 $ 28 $ 20 $ 56

Debt and Credit Facilities

Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2015
Long-term Debt, Unclassified [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES In October 2015 we sold $ 750 of senior unsecured notes due 2025 (2025 Notes). The 2025 Notes bear interest at 3.375% per year and, unless previously redeemed, will mature on November 1, 2025. In 2015 we repaid $ 500 of our senior unsecured notes that were due on January 15, 2015. Our commercial paper program allows us to have a maximum of $1,250 in commercial paper outstanding, with maturities up to 397 days from the date of issuance. On December 31, 2015 there were no amounts outstanding under our commercial paper program. Summary of Total Debt 2015 2014 Senior unsecured notes: Rate Due 3.000% 1/15/2015 $ — $ 500 2.000% 9/30/2016 750 750 1.300% 4/1/2018 599 598 4.375% 1/15/2020 498 498 3.375% 5/15/2024 610 605 3.375% 11/1/2025 750 — 4.100% 4/1/2043 395 395 4.375% 5/15/2044 398 398 Commercial paper — 200 Other 22 29 Total debt $ 4,022 $ 3,973 Less current maturities 769 727 Total long-term debt $ 3,253 $ 3,246 Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on December 31, 2015 . We have lines of credit, issued by various financial institutions, available to fund our day-to-day operating needs. On December 31, 2015 we had $ 1,236 of borrowing capacity available under all of our existing credit facilities. On December 31, 2015 the total unamortized debt issuance costs incurred in connection with our outstanding notes were $ 24 . The fair value of long-term debt (including current maturities and excluding the interest rate hedge) on December 31, 2015 and 2014 was $ 4,009 and $3,811 . Substantially all of our long-term debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments. Interest expense, including required fees incurred on outstanding debt and credit facilities, which is included in other expense totaled $108 , $113 , and $83 in 2015 , 2014 and 2013 .

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2015
Capital Stock [Abstract]
Capital Stock	CAPITAL STOCK Dividends Declared per Share of Common Stock 2015 Quarter Mar 31 Jun 30 Sep 30 Dec 31 $ 0.345 $ 0.345 $ 0.345 $ 0.380 Share Repurchases In 2015 we repurchased 7.4 million shares at a cost of $ 700 under our repurchase programs. The manner, timing and amount of purchases is determined by management based on an evaluation of market conditions, stock price and other factors and is subject to regulatory considerations. Purchases are made from time-to-time in the open market, in privately negotiated transactions or otherwise. On December 31, 2015 the total dollar value of shares that could be purchased under our authorized repurchase programs was $ 1,883 . Other Capital Stock Information Shares reserved for future compensation grants of our common stock were 15 million and 19 million at December 31, 2015 and 2014 . We have 0.5 million authorized shares of $1 par value preferred stock, none of which is outstanding. Stock Options We have long-term incentive plans from which we grant stock options to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the closing quoted price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments. We measure the cost of employee stock options based on the grant-date fair value and recognize that cost using the straight-line method over the period during which a recipient is required to provide services in exchange for the options, typically the vesting period. The weighted-average fair value per share of options is estimated on the date of grant using the Black-Scholes option pricing model. Option Value and Assumptions 2015 2014 2013 Weighted-average fair value per share $ 22.55 $ 15.80 $ 15.24 Assumptions: Risk-free interest rate 1.8 % 2.1 % 1.3 % Expected dividend yield 1.6 % 1.8 % 1.9 % Expected stock price volatility 25.5 % 20.2 % 27.9 % Expected option life 7.3 years 7.1 years 7.1 years The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on the historical volatility of our stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data. Summary of 2015 Stock Option Activity Shares (in millions) Weighted Weighted-Average Aggregate Outstanding January 1 15.2 $ 59.97 Granted 2.4 93.06 Exercised (2.4 ) 53.31 Cancelled (0.3 ) 73.56 Outstanding December 31 14.9 $ 65.85 5.7 $ 402.9 Exercisable December 31 8.3 $ 56.67 3.9 $ 302.2 Options expected to vest 6.0 $ 77.02 7.9 $ 95.9 The aggregate intrinsic value, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, of options exercised was $ 98 , $113 , and $97 during 2015, 2014 and 2013 . Exercise prices for options outstanding ranged from $38.71 to $102.27 on December 31, 2015 . On December 31, 2015 there was $79 of unrecognized compensation cost related to nonvested stock options granted under the long-term incentive plans; that cost is expected to be recognized over the weighted-average period of approximately 1.6 years . Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the closing quoted price of our common stock on the day prior to the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals during that three-year performance cycle. The fair value of PSUs is determined based on the closing quoted price of our common stock on the day prior to the date of grant. Summary of 2015 RSU and PSU Activity Shares Weighted RSUs PSUs RSUs PSUs Nonvested on January 1 1.3 0.3 $ 65.04 $ 66.18 Granted 0.6 0.1 88.47 92.96 Vested (0.7 ) — 60.54 54.31 Canceled (0.1 ) (0.1 ) 74.35 54.03 Nonvested on December 31 1.1 0.3 $ 79.71 $ 79.02 On December 31, 2015 there was $53 of unrecognized compensation cost related to nonvested RSUs. That cost is expected to be recognized as expense over the weighted-average period of approximately 1.0 year . The weighted-average grant date fair value per share of RSUs granted was $88.47 and $76.61 in 2015 and 2014. The fair value of RSUs vested in 2015 was $43 . On December 31, 2015 there was $18 of unrecognized compensation cost related to nonvested PSUs; that cost is expected to be recognized as expense over the weighted-average period of approximately 1.3 years. Employee Stock Purchase Plans (ESPP) Full- and part-time employees may participate in our ESPP provided they meet certain eligibility requirements. The purchase price for our common stock under the terms of the ESPP is defined as 95% of the closing stock price on the last trading day of a purchase period. We issued 157,931 and 150,167 shares under the ESPP during 2015 and 2014 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Our effective tax rate was 17.1% , 55.6% and 17.0% for 2015, 2014 and 2013. The effective income tax rate for 2014 includes the tax impacts of the establishment of a European regional headquarters and the cash repatriation which was executed in 2015. In 2015 we retroactively adopted ASU 2015-17 Income Taxes (Topic 740) Balance Sheet Classification of Deferred Taxes that amends the balance sheet classification of deferred taxes. Earnings Before Income Taxes 2015 2014 2013 United States $ 475 $ 355 $ 193 International 1,260 805 1,019 Total $ 1,735 $ 1,160 $ 1,212 Components of Income Tax Expense 2015 2014 2013 Current income tax expense United States federal $ 78 $ 213 $ 79 United States state and local 23 26 29 International 108 346 75 Total current income tax expense $ 209 $ 585 $ 183 Deferred income tax expense (benefit) United States federal $ 2 $ 9 $ (52 ) United States state and local 8 (16 ) (4 ) International 77 67 79 Total deferred income tax expense (benefit) $ 87 $ 60 $ 23 Total income tax expense $ 296 $ 645 $ 206 Interest and penalties included in other income (expense), net were ($ 4 ), $ 8 and $ 12 in 2015, 2014 and 2013. In 2013 we recorded income tax benefits related to favorable audit resolutions in multiple jurisdictions. The United States federal deferred income tax expense (benefit) includes the utilization of net operating loss carryforwards of $ 79 , $ 78 and $ 16 in 2015 , 2014 and 2013 . Reconciliation of the United States Federal Statutory Income Tax Rate to our Effective Income Tax Rate 2015 2014 2013 United States federal statutory rate 35.0 % 35.0 % 35.0 % Add (deduct): United States state and local income taxes, less federal deduction 2.1 2.2 1.4 Foreign income tax at rates other than 35% (17.6 ) 4.9 (13.7 ) Tax related to repatriation of foreign earnings (3.9 ) 10.1 — Other 1.5 3.4 (5.7 ) 17.1 % 55.6 % 17.0 % Deferred Income Tax Assets and Liabilities 2015 2014 Deferred income tax assets: Inventories $ 513 $ 585 Product related liabilities 116 167 Other accrued expenses 206 226 Depreciation and amortization 4 44 State income taxes 43 68 Share-based compensation 79 90 Net operating loss carryforwards 47 123 Other 143 143 Total deferred income tax assets $ 1,151 $ 1,446 Less valuation allowances (47 ) (42 ) Total deferred income tax assets, net $ 1,104 $ 1,404 Deferred income tax liabilities: Depreciation and amortization $ (586 ) $ (666 ) Undistributed earnings (50 ) (132 ) Other (26 ) (54 ) Total deferred income tax liabilities $ (662 ) $ (852 ) Net deferred income tax assets $ 442 $ 552 Reported as: Noncurrent assets—Other $ 477 $ 594 Noncurrent liabilities—Other liabilities (35 ) (42 ) Total $ 442 $ 552 Accrued interest and penalties were $ 30 and $ 26 , which was reported in accrued expenses and other liabilities, both current and noncurrent, on December 31, 2015 and 2014. Net operating loss carryforwards totaling $152 on December 31, 2015 are available to reduce future taxable earnings of certain domestic and foreign subsidiaries. United States loss carryforwards of $81 expire through 2028. International loss carryforwards of $71 began to expire in 2015; however, some have no expiration. Of these carryforwards, $43 are subject to a full valuation allowance. We also have a tax credit carryforward of $36 with a full valuation allowance. These credits have no expiration; however, we do not anticipate generating income tax in excess of the credits in the foreseeable future. No provision has been made for United States federal and state income taxes or international income taxes that may result from future remittances of the undistributed earnings of foreign subsidiaries that are determined to be indefinitely reinvested ( $7,166 on December 31, 2015 ). Determination of the amount of any unrecognized deferred income tax liability on these is not practicable. Changes in the Amounts Recorded for Uncertain Income Tax Positions 2015 2014 Balance at beginning of year $ 315 $ 204 Increases related to current year income tax positions 21 133 Increases related to prior year income tax positions 3 23 Decreases related to prior year income tax positions: Settlements and resolutions of income tax audits (9 ) (33 ) Statute of limitations expirations (6 ) (1 ) Foreign currency translation (11 ) (6 ) Other — (5 ) Balance at end of year $ 313 $ 315 Reported as: Current liabilities—Income taxes $ 9 $ 3 Noncurrent liabilities—Other liabilities 304 312 Total $ 313 $ 315 Our income tax expense could have been reduced by $304 and $307 on December 31, 2015 and 2014, had these uncertain income tax positions been favorably resolved. It is reasonably possible that the amount of unrecognized tax benefits will significantly change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, tax payments, competent authority proceedings related to transfer pricing or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements. We are not able to reasonably estimate the amount or the future periods in which changes in unrecognized tax benefits may be resolved; however, we anticipate certain unrecognized tax benefits related to some examinations to be resolved within the next twelve months. As a result, it is reasonably possible that the gross unrecognized tax benefits could decrease by amounts up to $ 55 because of these potential resolved examinations. Interest and penalties incurred associated with uncertain tax positions are included in other income (expense), net. In the normal course of business, income tax authorities in various income tax jurisdictions both within the United States and internationally conduct routine audits of our income tax returns filed in prior years. These audits are generally designed to determine if individual income tax authorities are in agreement with our interpretations of complex income tax regulations regarding the allocation of income to the various income tax jurisdictions. Income tax years are open from 2010 through the current year for the United States federal jurisdiction; income tax years open for our other major jurisdictions range from 2005 through the current year.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2015
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Retirement Plans	RETIREMENT PLANS Defined Contribution Plans We provide certain employees with defined contribution plans. A portion of our retirement plan expense under the defined contribution plans is funded with Stryker common stock. The use of Stryker common stock represents a non-cash operating activity that is not reflected in the consolidated statements of cash flows. 2015 2014 2013 Plan expense $ 148 $ 132 $ 132 Expense funded with Stryker common stock 20 18 16 Stryker common stock held by plan Dollar amount 203 198 150 Shares (in millions of shares) 2.2 2.1 2.0 Value as a percentage of total plan assets 11 % 11 % 9 % Defined Benefit Plans Certain of our subsidiaries have both funded and unfunded defined benefit pension plans covering some or all of their employees. Substantially all of the defined benefit pension plans have projected benefit obligations in excess of plan assets. Discount Rate The discount rates were selected using a hypothetical portfolio of high quality bonds on December 31 that would provide the necessary cash flows to match our projected benefit payments. Expected Return on Plan Assets The expected return on plan assets is determined by applying the target allocation in each asset category of plan investments to the anticipated return for each asset category based on historical and projected returns. Components of Net Periodic Pension Cost 2015 2014 2013 Net periodic benefit cost: Service cost $ (36 ) $ (26 ) $ (30 ) Interest cost (10 ) (13 ) (13 ) Expected return on plan assets 11 10 10 Amortization of prior service cost and transition amount 1 1 1 Recognized actuarial loss (13 ) (7 ) (8 ) Net periodic benefit cost $ (47 ) $ (35 ) $ (40 ) Changes in assets and benefit obligations recognized in OCI: Net actuarial gain (loss) $ 26 $ (88 ) $ 28 Recognized net actuarial loss 13 7 8 Prior service cost and transition amount (1 ) 4 (1 ) Total recognized in OCI $ 38 $ (77 ) $ 35 Total recognized in net periodic benefit cost and OCI $ (9 ) $ (112 ) $ (5 ) Assumptions Weighted-average rates used to determine net periodic benefit cost: Discount rate 2.0 % 3.2 % 2.9 % Expected return on plan assets 4.0 % 3.7 % 3.7 % Rate of compensation increase 2.9 % 2.9 % 3.0 % Weighted-average discount rate used to determine projected benefit obligations 2.1 % 2.0 % 3.2 % Investment Strategy The investment strategy for our defined benefit pension plans is to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk tolerances. 2015 2014 Funded status Fair value of plan assets $ 289 $ 310 Benefit obligations (529 ) (570 ) Funded status $ (240 ) $ (260 ) Reported as: Current liabilities—accrued compensation $ (1 ) $ (1 ) Noncurrent liabilities—other liabilities (239 ) (259 ) Pre-tax amounts recognized in AOCI Unrecognized net actuarial loss (155 ) (195 ) Unrecognized prior service cost 13 15 Total $ (142 ) $ (180 ) The estimated net actuarial loss for the defined benefit pension plans to be reclassified from AOCI into net periodic benefit cost is $7 in 2016. We estimate that an immaterial amount of amortization of prior service cost and transition amount for the defined benefit pension plans will be reclassified from AOCI into net periodic benefit cost in 2016. Change in Benefit Obligations 2015 2014 Beginning Projected benefit obligations $ 570 $ 456 Service cost 36 26 Interest cost 10 13 Foreign exchange impact (43 ) (43 ) Employee contributions 6 6 Actuarial (gains) losses (21 ) 134 Plan amendments — (5 ) Acquisitions — 5 Benefits paid (29 ) (22 ) Ending Projected benefit obligations $ 529 $ 570 Ending Accumulated benefit obligations $ 505 $ 533 Change in Plan Assets 2015 2014 Beginning Fair value of plan assets $ 310 $ 281 Actual return 2 46 Employer contributions 16 18 Employee contributions 6 6 Foreign exchange impact (18 ) (24 ) Acquisition — 3 Benefits paid (27 ) (20 ) Ending Fair value of plan assets $ 289 $ 310 Weighted-Average Target and Actual Allocation of Plan Assets by Asset Category 2015 2014 Target Actual Actual Equity securities 29 % 31 % 30 % Debt securities 50 48 48 Other 21 21 22 Total 100 % 100 % 100 % Valuation of Our Pension Plan Assets by Pricing Categories Level 2015 1 2 3 Total Cash and cash equivalents $ 6 $ — $ — $ 6 Equity securities 67 22 — 89 Corporate debt securities 135 — — 135 Other 19 9 31 59 Total $ 227 $ 31 $ 31 $ 289 2014 Cash and cash equivalents $ 6 $ — $ — $ 6 Equity securities 99 26 — 125 Corporate debt securities 121 — — 121 Other 17 8 33 58 Total $ 243 $ 34 $ 33 $ 310 Our Level 3 pension plan assets (See Note 4 for an explanation of our fair value hierarchy) consist primarily of guaranteed investment contracts with insurance companies. The insurance contracts guarantee us principal repayment and a fixed rate of return. Our valuation of Level 3 assets is based on third-party actuarial valuations that are an estimation of the surrender value of the guaranteed investment contract between us and the insurance company. The surrender value equals the actuarial value of the notional investments underlying the guaranteed investment contract, using the actuarial assumptions as stated in the guaranteed investment contract. Rollforward of Level 3 Pension Plan Assets 2015 2014 Balance on January 1 $ 33 $ 22 Actual return on plan assets held at the reporting date (2 ) 11 Balance on December 31 $ 31 $ 33 Estimated Future Benefit Payments 2016 2017 2018 2019 2020 2021-2025 $ 14 $ 14 $ 13 $ 14 $ 13 $ 77 We expect to contribute $18 to our defined benefit pension plans in 2016.

Segment and Geographic Data

Segment and Geographic Data	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment and Geographic Data	SEGMENT AND GEOGRAPHIC DATA We segregate our operations into three reportable business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; and reprocessed and remanufactured medical devices and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Corporate and Other category shown in the table below includes corporate and global manufacturing operations and administration, central research and development initiatives, interest expense, interest and marketable securities income and share-based compensation, which includes compensation related to both employee and director stock option, restricted stock unit and performance stock unit grants. Certain prior year amounts have been reclassified to conform with the current year presentation of our segments. Results by Reportable Segments 2015 2014 2013 Orthopaedics $ 4,223 $ 4,153 $ 3,949 MedSurg 3,895 3,781 3,414 Neurotechnology & Spine 1,828 1,741 1,658 Net sales $ 9,946 $ 9,675 $ 9,021 Orthopaedics $ 290 $ 319 $ 273 MedSurg 117 113 84 Neurotechnology & Spine 132 134 135 Segment depreciation and amortization $ 539 $ 566 $ 492 Corporate and Other 51 20 19 Total depreciation and amortization $ 590 $ 586 $ 511 Orthopaedics $ 1,487 $ 1,410 $ 1,353 MedSurg 822 850 802 Neurotechnology & Spine 474 476 430 Segment operating income $ 2,783 $ 2,736 $ 2,585 Items not allocated to segments: Corporate and Other $ (302 ) $ (322 ) $ (314 ) Acquisition & integration-related charges (35 ) (102 ) (98 ) Amortization of intangible assets (210 ) (188 ) (138 ) Restructuring related charges (132 ) (117 ) (63 ) Rejuvenate and related charges (296 ) (761 ) (622 ) Regulatory and legal matters 53 — (69 ) Donation — — (25 ) Consolidated operating income $ 1,861 $ 1,246 $ 1,256 Total Assets and Capital Spending by Reportable Segments 2015 2014 2013 Orthopaedics $ 6,149 $ 8,357 $ 7,756 MedSurg 5,341 5,557 4,533 Neurotechnology & Spine 3,904 3,684 3,017 Total segment assets $ 15,394 $ 17,598 $ 15,306 Corporate and Other 853 (319 ) 93 Total assets $ 16,247 $ 17,279 $ 15,399 Orthopaedics $ 95 $ 80 $ 89 MedSurg 89 77 59 Neurotechnology & Spine 28 20 16 Total segment capital spending $ 212 $ 177 $ 164 Corporate and Other 58 56 31 Capital spending $ 270 $ 233 $ 195 Our reportable segments are business units that offer different products and services and are managed separately because each business requires different manufacturing, technology and marketing strategies. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 1 to the Consolidated Financial Statements. We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, restructuring related charges, reserves for certain product recall matters, reserves for certain legal and regulatory matters, a donation to an educational institution, other income (expense), net and income taxes. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally cash and cash equivalents, marketable securities and property, plant and equipment. The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe, Middle East, Africa (EMEA); Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are attributable to a geographic area based upon the customer’s country of domicile. Net Property, Plant and Equipment Based on Geographic Physical Location Net Sales Net Property, Plant & Equipment 2015 2014 2013 2015 2014 United States $ 7,116 $ 6,558 $ 5,984 $ 626 $ 539 Europe, Middle East, Africa 1,267 1,371 1,316 432 417 Asia Pacific 1,251 1,368 1,319 116 119 Other foreign countries 312 378 402 25 23 Total $ 9,946 $ 9,675 $ 9,021 $ 1,199 $ 1,098

Summary of Quarterly Data (Unau

Summary of Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Summary of Quarterly Data (Unaudited)	SUMMARY OF QUARTERLY DATA (UNAUDITED) 2015 Quarter Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 2,379 $ 2,432 $ 2,420 $ 2,715 Gross profit 1,553 1,605 1,624 1,820 Earnings before income taxes 377 401 345 612 Net earnings 224 392 301 522 Net earnings per share of common stock: Basic $ 0.59 $ 1.04 $ 0.80 $ 1.39 Diluted $ 0.58 $ 1.03 $ 0.79 $ 1.38 Market price of common stock: High $ 96.18 $ 97.94 $ 105.34 $ 100.51 Low $ 89.81 $ 90.19 $ 91.73 $ 90.30 Dividends declared per share of common stock $ 0.345 $ 0.345 $ 0.345 $ 0.380 2014 Quarter Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 2,305 $ 2,363 $ 2,389 $ 2,618 Gross profit 1,529 1,548 1,560 1,718 Earnings before income taxes 107 167 425 461 Net earnings 70 128 57 260 Net earnings per share of common stock: Basic $ 0.19 $ 0.34 $ 0.16 $ 0.68 Diluted $ 0.18 $ 0.33 $ 0.16 $ 0.67 Market price of common stock: High $ 83.86 $ 86.93 $ 85.91 $ 98.24 Low $ 74.02 $ 75.78 $ 78.91 $ 77.87 Dividends declared per share of common stock $ 0.305 $ 0.305 $ 0.305 $ 0.345 The price quotations reported above were supplied by the New York Stock Exchange.

Significant Accounting Polici23

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Nature of Operations	Stryker Corporation (the "Company," "we," "us," or "our") is a global leader in medical technology. Our products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Basis of Presentation and Consideration	The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Certain prior year amounts have been reclassified to conform with the presentation of our Consolidated Financial Statements and in Note 13 for 2015.
Use of Estimates	: The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates
Revenue Recognition	Sales are recognized when revenue is realized or realizable and has been earned. Our policy is to recognize revenue when title to the product, ownership and risk of loss transfer to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most orthopaedics products, when we receive appropriate notification that the product has been used or implanted. A provision for estimated sales returns, discounts, rebates and other sales incentives is recorded as a reduction of net sales in the same period that the revenue is recognized. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales	Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses	Research and development costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses	Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation	Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in earnings.
Cash Equivalents	Highly liquid investments with remaining stated maturities of three months or less when purchased are considered cash equivalents and recorded at cost.
Marketable Securities	Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities.
Accounts Receivable	Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience and expected future trends. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories	Inventories are stated at the lower of cost or market, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to market prices.
Financial Instruments	Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. With the exception of our long-term debt, which is discussed in further detail in Note 9, our estimates of fair value for financial instruments approximate their carrying amounts on December 31, 2015 and 2014 . All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recorded in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and loses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method. We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is an other-than-temporary impairment. The resulting losses from other-than-temporary impairments of available-for-sale marketable securities are included in earnings.
Derivatives	All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. These nonfunctional currency exposures principally relate to intercompany receivables and payables arising from intercompany purchases of manufactured products. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period, with resulting gains (losses) included in earnings. Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the consolidated balance sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in other income (expense), net or cost of goods sold in the consolidated statements of earnings, depending on the underlying transaction that is being hedged. We report our derivative instruments on a gross basis. Interest rate derivative instruments designated as fair value hedges are being used to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. For derivative instruments designated as net investment hedges of our foreign operations, the gain or loss is recorded in the cumulative translation adjustment within AOCI together with the offsetting loss or gain of the hedged exposure of the underlying foreign operations. Any ineffective portion of the net investment hedges is reported in earnings during the period of change. Hedge effectiveness for equity forward contracts and foreign exchange net investment hedge forward contracts is assessed by comparing changes in fair value due to changes in spot rates for both the derivative and the hedged item.
Property, Plant and Equipment	Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to ten years for machinery and equipment.
Goodwill and Other Intangible Assets	Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase revenues and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. The fair values of other identifiable intangible assets are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below. In certain of our acquisitions, we acquire in-process research and development (IPRD) which are indefinite-lived intangible assets. IPRD where research has been completed becomes a determinable-lived intangible asset and IPRD determined to have no future use becomes impaired.
Goodwill and Long-Lived Asset Impairment Tests	We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value. We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell.
Share-Based Compensation	We use share based compensation in the form of stock options, restricted stock units (RSUs) and performance-based restricted stock units (PSUs). Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized to date associated with grants that are not expected to vest will be reversed.
Income Taxes	Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities during the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate. We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
New Accounting Pronouncements Not Yet Adopted	In April 2015 the FASB issued ASU 2015-03, Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update requires an entity to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability consistent with debt discounts and is effective for financial statements issued for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. We adopted this standard on January 1, 2016 and do not expect it to have a material impact on the Consolidated Financial Statements. In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This guidance, which is effective for financial statements issued for fiscal years beginning after December 15, 2017, outlines a single, comprehensive model for accounting for revenue from contracts with customers. We plan to adopt this standard on January 1, 2018. We are still evaluating what impact, if any, that the standard will have on our financial statements.

Changes in Accumulated Other 24

Changes in Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2015
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	2015 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ 3 $ (136 ) $ 13 $ (134 ) $ (254 ) OCI before reclassifications 1 15 2 (362 ) (344 ) Tax (benefit) expense on OCI (1 ) (4 ) 2 (28 ) (31 ) Reclassifications out of AOCI, net Cost of Sales — 8 (19 ) — (11 ) Other (income) expense (4 ) — — — (4 ) Income tax expense (benefit) 1 (2 ) 6 — 5 Net current period OCI $ (3 ) $ 17 $ (9 ) $ (390 ) $ (385 ) Ending $ — $ (119 ) $ 4 $ (524 ) $ (639 ) 2014 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (81 ) $ 7 $ 306 $ 232 OCI before reclassifications 12 (72 ) 10 (440 ) (490 ) Tax (benefit) expense on OCI (2 ) 22 (4 ) — 16 Reclassifications out of AOCI, net Cost of Sales — (6 ) (1 ) — (7 ) Other (income) expense (9 ) — — — (9 ) Income tax expense (benefit) 2 1 1 — 4 Net current period OCI $ 3 $ (55 ) $ 6 $ (440 ) $ (486 ) Ending $ 3 $ (136 ) $ 13 $ (134 ) $ (254 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	2015 2014 Cash and cash equivalents $ 3,379 $ 1,795 Trading marketable securities 82 80 Level 1 - Assets $ 3,461 $ 1,875 Available-for-sale marketable securities Corporate and asset-backed debt securities $ 214 $ 1,525 Foreign government debt securities 96 726 United States agency debt securities 120 382 United States treasury debt securities 264 474 Certificates of deposit 8 110 Other — 12 Total available-for-sale marketable securities $ 702 $ 3,229 Foreign currency exchange forward contracts 69 32 Interest rate swap asset 15 10 Level 2 - Assets $ 786 $ 3,271 Total assets measured at fair value $ 4,247 $ 5,146 Deferred compensation arrangements $ 82 $ 80 Level 1 - Liabilities $ 82 $ 80 Foreign currency exchange forward contracts $ 10 $ 12 Interest rate swap liability 4 — Level 2 - Liabilities $ 14 $ 12 Contingent consideration Beginning balance $ 48 $ 59 Additions 11 — Losses included in earnings — 4 Settlements (3 ) (15 ) Balance at the end of the period $ 56 $ 48 Level 3 - Liabilities $ 56 $ 48 Total liabilities measured at fair value $ 152 $ 140
Available-for-sale Securities	2015 2014 Due in one year or less $ 588 $ 430 Due after one year through three years $ 114 $ 2,505 Due after three years $ — $ 294
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	Number of Investments Fair Value Corporate and Asset-Backed 98 $ 117 Foreign Government 10 30 United States Agency 8 18 United States Debt 15 38 Certificate of Deposit 6 4 Total 137 $ 207

Derivative Instruments (Tables)

Derivative Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Designated Non-Designated Total 2015 Gross notional amount $ 889 $ 4,061 $ 4,950 Maximum term in days 546 Fair value: Other current assets $ 27 $ 41 $ 68 Other noncurrent assets 1 — 1 Other current liabilities (6 ) (3 ) (9 ) Other noncurrent liabilities (1 ) — (1 ) Total fair value $ 21 $ 38 $ 59 2014 Gross notional amount $ 357 $ 2,085 $ 2,442 Maximum term in days 546 Fair value: Other current assets $ 18 $ 12 $ 30 Other noncurrent assets 2 — 2 Other current liabilities — (12 ) (12 ) Total fair value $ 20 $ — $ 20
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	Recorded in: 2015 2014 2013 Cost of sales $ 19 $ 1 $ — Other income (expense), net (22 ) (8 ) 3 Total $ (3 ) $ (7 ) $ 3
Schedule of Derivative Instruments	2015 2014 Gross notional amount $ 500 $ 500 Fair value: Other noncurrent assets 15 10 Long-term debt (15 ) (10 ) Total fair value $ — $ —

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions	2015 2014 Other SBi Berchtold PST Other Purchase price paid $ 138 $ 365 $ 184 $ 120 $ 216 Contingent consideration 9 — — — — Total consideration $ 147 $ 365 $ 184 $ 120 $ 216 Tangible assets acquired: Cash — — 12 — — Inventory 10 23 22 7 5 Other assets 17 6 44 19 25 Liabilities (5 ) (2 ) (45 ) (31 ) (29 ) Intangible assets: Customer relationship 12 20 11 33 5 Trade name 2 — 7 — — Developed technology and patents 51 73 32 26 115 Other 2 1 — — — IPRD — 1 — — 2 Goodwill 58 243 101 66 93 $ 147 $ 365 $ 184 $ 120 $ 216 Weighted average life of intangible assets 10 12 8 14 12

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of the Company's Other Intangible Assets	Weighted Average Amortization Period (Years) Gross Less Net Developed technologies 2015 13 $ 1,597 $ 563 $ 1,034 2014 13 1,468 466 1,002 Customer relationships 2015 15 $ 788 $ 290 $ 498 2014 15 801 239 562 Patents 2015 11 $ 309 $ 191 $ 118 2014 12 293 175 118 Trademarks 2015 10 $ 109 $ 41 $ 68 2014 14 112 37 75 In-process research and development 2015 $ 25 $ — $ 25 2014 201 — 201 Other 2015 13 $ 108 $ 57 $ 51 2014 12 111 51 60 Total 2015 13 $ 2,936 $ 1,142 $ 1,794 2014 13 $ 2,986 $ 968 $ 2,018
Changes in the Net Carrying Amount of Goodwill by Segment	Changes in the Net Carrying Value of Goodwill by Segment Orthopaedics MedSurg Neurotechnology and Spine Total 2013 $ 2,227 $ 506 $ 1,111 $ 3,844 Additions and adjustments 186 231 23 440 Foreign exchange (27 ) (11 ) (60 ) (98 ) 2014 $ 2,386 $ 726 $ 1,074 $ 4,186 Additions and adjustments 20 46 — 66 Foreign exchange (62 ) 10 (64 ) (116 ) 2015 $ 2,344 $ 782 $ 1,010 $ 4,136
Estimated Amortization Expense	2016 2017 2018 2019 2020 $ 202 $ 183 $ 181 $ 165 $ 148

Contingencies and Commitments (

Contingencies and Commitments (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Purchase Obligations and Minimum Lease Payments	2016 2017 2018 2019 2020 Thereafter Purchase obligations $ 802 $ 125 $ 62 $ 55 $ 2 $ 67 Minimum lease payments $ 69 $ 51 $ 39 $ 28 $ 20 $ 56

Debt and Credit Facilities (Tab

Debt and Credit Facilities (Tables)	12 Months Ended
	Dec. 31, 2015
Long-term Debt, Unclassified [Abstract]
Maturities Of Long-Term Debt Disclosures	2015 2014 Senior unsecured notes: Rate Due 3.000% 1/15/2015 $ — $ 500 2.000% 9/30/2016 750 750 1.300% 4/1/2018 599 598 4.375% 1/15/2020 498 498 3.375% 5/15/2024 610 605 3.375% 11/1/2025 750 — 4.100% 4/1/2043 395 395 4.375% 5/15/2044 398 398 Commercial paper — 200 Other 22 29 Total debt $ 4,022 $ 3,973 Less current maturities 769 727 Total long-term debt $ 3,253 $ 3,246

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Capital Stock [Abstract]
Schedule of Dividends Declared	2015 Quarter Mar 31 Jun 30 Sep 30 Dec 31 $ 0.345 $ 0.345 $ 0.345 $ 0.380
Schedule of Fair Value Assumptions	2015 2014 2013 Weighted-average fair value per share $ 22.55 $ 15.80 $ 15.24 Assumptions: Risk-free interest rate 1.8 % 2.1 % 1.3 % Expected dividend yield 1.6 % 1.8 % 1.9 % Expected stock price volatility 25.5 % 20.2 % 27.9 % Expected option life 7.3 years 7.1 years 7.1 years
Summary of Stock Option Activity	Shares (in millions) Weighted Weighted-Average Aggregate Outstanding January 1 15.2 $ 59.97 Granted 2.4 93.06 Exercised (2.4 ) 53.31 Cancelled (0.3 ) 73.56 Outstanding December 31 14.9 $ 65.85 5.7 $ 402.9 Exercisable December 31 8.3 $ 56.67 3.9 $ 302.2 Options expected to vest 6.0 $ 77.02 7.9 $ 95.9
Summary of RSU and PSU Activity	Shares Weighted RSUs PSUs RSUs PSUs Nonvested on January 1 1.3 0.3 $ 65.04 $ 66.18 Granted 0.6 0.1 88.47 92.96 Vested (0.7 ) — 60.54 54.31 Canceled (0.1 ) (0.1 ) 74.35 54.03 Nonvested on December 31 1.1 0.3 $ 79.71 $ 79.02

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Earnings before Income Taxes	2015 2014 2013 United States $ 475 $ 355 $ 193 International 1,260 805 1,019 Total $ 1,735 $ 1,160 $ 1,212
Schedule of Provision for Income Taxes	2015 2014 2013 Current income tax expense United States federal $ 78 $ 213 $ 79 United States state and local 23 26 29 International 108 346 75 Total current income tax expense $ 209 $ 585 $ 183 Deferred income tax expense (benefit) United States federal $ 2 $ 9 $ (52 ) United States state and local 8 (16 ) (4 ) International 77 67 79 Total deferred income tax expense (benefit) $ 87 $ 60 $ 23 Total income tax expense $ 296 $ 645 $ 206
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations	2015 2014 2013 United States federal statutory rate 35.0 % 35.0 % 35.0 % Add (deduct): United States state and local income taxes, less federal deduction 2.1 2.2 1.4 Foreign income tax at rates other than 35% (17.6 ) 4.9 (13.7 ) Tax related to repatriation of foreign earnings (3.9 ) 10.1 — Other 1.5 3.4 (5.7 ) 17.1 % 55.6 % 17.0 %
Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities	2015 2014 Deferred income tax assets: Inventories $ 513 $ 585 Product related liabilities 116 167 Other accrued expenses 206 226 Depreciation and amortization 4 44 State income taxes 43 68 Share-based compensation 79 90 Net operating loss carryforwards 47 123 Other 143 143 Total deferred income tax assets $ 1,151 $ 1,446 Less valuation allowances (47 ) (42 ) Total deferred income tax assets, net $ 1,104 $ 1,404 Deferred income tax liabilities: Depreciation and amortization $ (586 ) $ (666 ) Undistributed earnings (50 ) (132 ) Other (26 ) (54 ) Total deferred income tax liabilities $ (662 ) $ (852 ) Net deferred income tax assets $ 442 $ 552 Reported as: Noncurrent assets—Other $ 477 $ 594 Noncurrent liabilities—Other liabilities (35 ) (42 ) Total $ 442 $ 552
Schedule of Unresolved Income Tax Positions	2015 2014 Balance at beginning of year $ 315 $ 204 Increases related to current year income tax positions 21 133 Increases related to prior year income tax positions 3 23 Decreases related to prior year income tax positions: Settlements and resolutions of income tax audits (9 ) (33 ) Statute of limitations expirations (6 ) (1 ) Foreign currency translation (11 ) (6 ) Other — (5 ) Balance at end of year $ 313 $ 315 Reported as: Current liabilities—Income taxes $ 9 $ 3 Noncurrent liabilities—Other liabilities 304 312 Total $ 313 $ 315

Retirement Plans (Tables)

Retirement Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Contribution Plan Disclosures	2015 2014 2013 Plan expense $ 148 $ 132 $ 132 Expense funded with Stryker common stock 20 18 16 Stryker common stock held by plan Dollar amount 203 198 150 Shares (in millions of shares) 2.2 2.1 2.0 Value as a percentage of total plan assets 11 % 11 % 9 %
Schedule of Defined Benefit Plans Disclosures	2015 2014 Funded status Fair value of plan assets $ 289 $ 310 Benefit obligations (529 ) (570 ) Funded status $ (240 ) $ (260 ) Reported as: Current liabilities—accrued compensation $ (1 ) $ (1 ) Noncurrent liabilities—other liabilities (239 ) (259 ) Pre-tax amounts recognized in AOCI Unrecognized net actuarial loss (155 ) (195 ) Unrecognized prior service cost 13 15 Total $ (142 ) $ (180 )
Schedule of Changes in Accumulated Postemployment Benefit Obligations	2015 2014 Beginning Projected benefit obligations $ 570 $ 456 Service cost 36 26 Interest cost 10 13 Foreign exchange impact (43 ) (43 ) Employee contributions 6 6 Actuarial (gains) losses (21 ) 134 Plan amendments — (5 ) Acquisitions — 5 Benefits paid (29 ) (22 ) Ending Projected benefit obligations $ 529 $ 570 Ending Accumulated benefit obligations $ 505 $ 533
Schedule of Changes in Fair Value of Plan Assets	2015 2014 Beginning Fair value of plan assets $ 310 $ 281 Actual return 2 46 Employer contributions 16 18 Employee contributions 6 6 Foreign exchange impact (18 ) (24 ) Acquisition — 3 Benefits paid (27 ) (20 ) Ending Fair value of plan assets $ 289 $ 310 Level 2015 1 2 3 Total Cash and cash equivalents $ 6 $ — $ — $ 6 Equity securities 67 22 — 89 Corporate debt securities 135 — — 135 Other 19 9 31 59 Total $ 227 $ 31 $ 31 $ 289 2014 Cash and cash equivalents $ 6 $ — $ — $ 6 Equity securities 99 26 — 125 Corporate debt securities 121 — — 121 Other 17 8 33 58 Total $ 243 $ 34 $ 33 $ 310
Schedule of Costs of Retirement Plans	2015 2014 2013 Net periodic benefit cost: Service cost $ (36 ) $ (26 ) $ (30 ) Interest cost (10 ) (13 ) (13 ) Expected return on plan assets 11 10 10 Amortization of prior service cost and transition amount 1 1 1 Recognized actuarial loss (13 ) (7 ) (8 ) Net periodic benefit cost $ (47 ) $ (35 ) $ (40 ) Changes in assets and benefit obligations recognized in OCI: Net actuarial gain (loss) $ 26 $ (88 ) $ 28 Recognized net actuarial loss 13 7 8 Prior service cost and transition amount (1 ) 4 (1 ) Total recognized in OCI $ 38 $ (77 ) $ 35 Total recognized in net periodic benefit cost and OCI $ (9 ) $ (112 ) $ (5 ) Assumptions Weighted-average rates used to determine net periodic benefit cost: Discount rate 2.0 % 3.2 % 2.9 % Expected return on plan assets 4.0 % 3.7 % 3.7 % Rate of compensation increase 2.9 % 2.9 % 3.0 % Weighted-average discount rate used to determine projected benefit obligations 2.1 % 2.0 % 3.2 %
Schedule of Allocation of Plan Assets	2015 2014 Target Actual Actual Equity securities 29 % 31 % 30 % Debt securities 50 48 48 Other 21 21 22 Total 100 % 100 % 100 %
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	2015 2014 Balance on January 1 $ 33 $ 22 Actual return on plan assets held at the reporting date (2 ) 11 Balance on December 31 $ 31 $ 33
Schedule of Expected Benefit Payments	2016 2017 2018 2019 2020 2021-2025 $ 14 $ 14 $ 13 $ 14 $ 13 $ 77

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	2015 2014 2013 Orthopaedics $ 4,223 $ 4,153 $ 3,949 MedSurg 3,895 3,781 3,414 Neurotechnology & Spine 1,828 1,741 1,658 Net sales $ 9,946 $ 9,675 $ 9,021 Orthopaedics $ 290 $ 319 $ 273 MedSurg 117 113 84 Neurotechnology & Spine 132 134 135 Segment depreciation and amortization $ 539 $ 566 $ 492 Corporate and Other 51 20 19 Total depreciation and amortization $ 590 $ 586 $ 511 Orthopaedics $ 1,487 $ 1,410 $ 1,353 MedSurg 822 850 802 Neurotechnology & Spine 474 476 430 Segment operating income $ 2,783 $ 2,736 $ 2,585 Items not allocated to segments: Corporate and Other $ (302 ) $ (322 ) $ (314 ) Acquisition & integration-related charges (35 ) (102 ) (98 ) Amortization of intangible assets (210 ) (188 ) (138 ) Restructuring related charges (132 ) (117 ) (63 ) Rejuvenate and related charges (296 ) (761 ) (622 ) Regulatory and legal matters 53 — (69 ) Donation — — (25 ) Consolidated operating income $ 1,861 $ 1,246 $ 1,256
Sales and Other Financial Information by Business Segment	2015 2014 2013 Orthopaedics $ 6,149 $ 8,357 $ 7,756 MedSurg 5,341 5,557 4,533 Neurotechnology & Spine 3,904 3,684 3,017 Total segment assets $ 15,394 $ 17,598 $ 15,306 Corporate and Other 853 (319 ) 93 Total assets $ 16,247 $ 17,279 $ 15,399 Orthopaedics $ 95 $ 80 $ 89 MedSurg 89 77 59 Neurotechnology & Spine 28 20 16 Total segment capital spending $ 212 $ 177 $ 164 Corporate and Other 58 56 31 Capital spending $ 270 $ 233 $ 195
Geographic Information on Net Sales and Long-Lived Assets	Net Sales Net Property, Plant & Equipment 2015 2014 2013 2015 2014 United States $ 7,116 $ 6,558 $ 5,984 $ 626 $ 539 Europe, Middle East, Africa 1,267 1,371 1,316 432 417 Asia Pacific 1,251 1,368 1,319 116 119 Other foreign countries 312 378 402 25 23 Total $ 9,946 $ 9,675 $ 9,021 $ 1,199 $ 1,098

Summary of Quarterly Data (Un35

Summary of Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Summary of Quarterly Data	2015 Quarter Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 2,379 $ 2,432 $ 2,420 $ 2,715 Gross profit 1,553 1,605 1,624 1,820 Earnings before income taxes 377 401 345 612 Net earnings 224 392 301 522 Net earnings per share of common stock: Basic $ 0.59 $ 1.04 $ 0.80 $ 1.39 Diluted $ 0.58 $ 1.03 $ 0.79 $ 1.38 Market price of common stock: High $ 96.18 $ 97.94 $ 105.34 $ 100.51 Low $ 89.81 $ 90.19 $ 91.73 $ 90.30 Dividends declared per share of common stock $ 0.345 $ 0.345 $ 0.345 $ 0.380 2014 Quarter Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 2,305 $ 2,363 $ 2,389 $ 2,618 Gross profit 1,529 1,548 1,560 1,718 Earnings before income taxes 107 167 425 461 Net earnings 70 128 57 260 Net earnings per share of common stock: Basic $ 0.19 $ 0.34 $ 0.16 $ 0.68 Diluted $ 0.18 $ 0.33 $ 0.16 $ 0.67 Market price of common stock: High $ 83.86 $ 86.93 $ 85.91 $ 98.24 Low $ 74.02 $ 75.78 $ 78.91 $ 77.87 Dividends declared per share of common stock $ 0.305 $ 0.305 $ 0.305 $ 0.345

Significant Accounting Polici36

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	4 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	40 years
Building and Building Improvements [Member] | Minimum [Member]
Property, plant and equipment useful life	3 years
Building and Building Improvements [Member] | Maximum [Member]
Property, plant and equipment useful life	30 years
Machinery and Equipment [Member] | Minimum [Member]
Property, plant and equipment useful life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, plant and equipment useful life	10 years

Subsequent Event (Details)

Subsequent Event (Details) $ in Millions	Feb. 01, 2016USD ($)
Sage Products [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Total consideration	$ 2,775

Changes in Accumulated Other 38

Changes in Accumulated Other Comprehensive Income Changes in Accumulated Other Comprehensive Income (Schedule of Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	$ (254)	$ 232
OCI before reclassifications	(344)	(490)
Tax (benefit) expense on OCI	(31)	16
Cost of sales	(3,344)	(3,319)	$ (3,002)
Other (income) expense	126	86	44
Income taxes	296	645	206
Other comprehensive income	(385)	(486)	103
Accumulated Other Comprehensive Income (Loss), End of Period	(639)	(254)	232
Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	5	4
Other comprehensive income	(385)	(486)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	(11)	(7)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (expense) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	(4)	(9)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other comprehensive income		(486)	103
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	3	0
OCI before reclassifications	1	12
Tax (benefit) expense on OCI	(1)	(2)
Accumulated Other Comprehensive Income (Loss), End of Period	0	3	0
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	1	2
Other comprehensive income	(3)	3
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	0	0
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (expense) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	(4)	(9)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	(136)	(81)
OCI before reclassifications	15	(72)
Tax (benefit) expense on OCI	(4)	22
Accumulated Other Comprehensive Income (Loss), End of Period	(119)	(136)	(81)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	(2)	1
Other comprehensive income	17	(55)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	8	(6)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (expense) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	0	0
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	13	7
OCI before reclassifications	2	10
Tax (benefit) expense on OCI	2	(4)
Accumulated Other Comprehensive Income (Loss), End of Period	4	13	7
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	6	1
Other comprehensive income	(9)	6
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	(19)	(1)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (expense) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	0	0
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	(134)	306
OCI before reclassifications	(362)	(440)
Tax (benefit) expense on OCI	(28)	0
Accumulated Other Comprehensive Income (Loss), End of Period	(524)	(134)	$ 306
Accumulated Translation Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	0	0
Other comprehensive income	(390)	(440)
Accumulated Translation Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	0	0
Accumulated Translation Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (expense) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	$ 0	$ 0

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Interest Receivable		$ 2
Marketable securities, gain (loss)		$ 14	$ 28	$ 24
Asset-backed Securities [Member] | Standard & Poor's, A Rating [Member] | Fitch, A Rating [Member] | Moody's, A2 Rating [Member]
Percent of investments with credit quality ratings less than single A and A2		1.00%

Fair Value Measurements (Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
ASSETS
Available-for-sale marketable securities	$ 700	$ 3,205
Total assets measured at fair value	4,247	5,146
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Settlements		(15)
Total liabilities measured at fair value	152	140
(Level 1)
ASSETS
Available-for-sale marketable securities	3,379	1,795
Total assets measured at fair value	3,461	1,875
Liabilities:
Deferred compensation arrangements	82	80
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Total liabilities measured at fair value	82	80
(Level 1) | Trading Securities
ASSETS
Trading marketable securities	82	80
(Level 2)
ASSETS
Total assets measured at fair value	786	3,271
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Total liabilities measured at fair value	14	12
(Level 2) | Foreign Exchange Contract [Member]
ASSETS
Foreign currency exchange forward contracts	69	32
Interest rate swap asset	69	32
Liabilities:
Foreign currency exchange forward contracts	10	12
(Level 2) | Interest Rate Swap [Member]
ASSETS
Foreign currency exchange forward contracts	15	10
Interest rate swap asset	15	10
Liabilities:
Interest rate swap liability	4	0
(Level 2) | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	702	3,229
(Level 2) | Asset-backed Securities [Member] | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	214	1,525
(Level 2) | Foreign Government Debt Securities [Member] | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	96	726
(Level 2) | US Government Agencies Debt Securities [Member] | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	120	382
(Level 2) | US Treasury Securities [Member] | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	264	474
(Level 2) | Certificates of Deposit [Member] | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	8	110
(Level 2) | Total available-for-sale marketable securities | Corporate and asset-backed debt securities
ASSETS
Available-for-sale marketable securities	0	12
(Level 3)
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Beginning balance	48	59
Additions	11	0
Losses included in earnings		4
Settlements	(3)
Balance at the end of the period	56	48
Total liabilities measured at fair value	$ 56	$ 48

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Available-For-Sale Securities) (Details) $ in Millions	Dec. 31, 2015USD ($)
Fair Value Disclosures [Abstract]
Available-for-sale securities, debt maturities, next twelve months, amortized cost basis	$ 588
Available-for-sale securities, debt maturities, after one through three years, amortized cost basis	114
Available-for-sale securities, debt maturities, after three years, amortized cost basis	0
Available-for-sale securities, debt maturities, next twelve months, fair value	430
Available-for-sale securities, debt maturities, one through three years, fair value	2,505
Available-for-sale securities, debt maturities, after three years, fair value	$ 294

Fair Value Measurements (Unreal

Fair Value Measurements (Unrealized Losses And Fair Value Of Investments With Unrealized Losses) (Details) $ in Millions	Dec. 31, 2015USD ($)investment
Total, number of investments | investment	137
Total, fair value | $	$ 207
Asset-backed Securities [Member]
Total, number of investments | investment	98
Total, fair value | $	$ 117
Foreign Government Debt Securities [Member]
Total, number of investments | investment	10
Total, fair value | $	$ 30
US Government Agencies Debt Securities [Member]
Total, number of investments | investment	8
Total, fair value | $	$ 18
US Treasury Securities [Member]
Total, number of investments | investment	15
Total, fair value | $	$ 38
Certificates of Deposit [Member]
Total, number of investments | investment	6
Total, fair value | $	$ 4

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Ineffectiveness on net investment hedges	$ 0
Senior Unsecured Notes 3.375% due 2024 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Proceeds from Unsecured Notes Payable	600
Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of designated net investment hedges	21
Foreign Exchange Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	4,950	$ 2,442
Foreign Exchange Contract [Member] | Other Noncurrent Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Asset, Fair Value, Gross Asset	1	2
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains on derivatives designated as hedges	17	15
Notional amount	889	357
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Other Noncurrent Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Asset, Fair Value, Gross Asset	1	2
Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Asset, Fair Value, Gross Asset	0	0
Interest Rate Swap [Member] | Other Noncurrent Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Asset, Fair Value, Gross Asset	15	10
Interest Rate Swap [Member] | Other Noncurrent Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest Rate Cash Flow Hedge Liability at Fair Value	4
Interest Rate Swap [Member] | Long-term Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Asset, Fair Value, Gross Liability	15	10
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	375
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	$ 500	$ 500	$ 500

Derivative Instruments (Forward

Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign Exchange Contract [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Derivative [Line Items]
Notional amount	$ 4,950	$ 2,442
Maximum term	546 days	546 days
Derivative, fair value, net	$ 59	$ 20
Other Current Assets [Member]
Derivative [Line Items]
Derivative asset	68	30
Noncurrent Assets- Other [Member]
Derivative [Line Items]
Derivative asset	1	2
Accrued Expenses and Other Current Liabilities [Member]
Derivative [Line Items]
Derivative liability	(9)	(12)
Other Noncurrent Liabilities [Member]
Derivative [Line Items]
Derivative liability	(1)
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional amount	889	357
Derivative, fair value, net	21	20
Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivative [Line Items]
Derivative asset	27	18
Designated as Hedging Instrument [Member] | Noncurrent Assets- Other [Member]
Derivative [Line Items]
Derivative asset	1	2
Designated as Hedging Instrument [Member] | Accrued Expenses and Other Current Liabilities [Member]
Derivative [Line Items]
Derivative liability	(6)	0
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative [Line Items]
Derivative liability	(1)
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional amount	4,061	2,085
Derivative, fair value, net	38	0
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivative [Line Items]
Derivative asset	41	12
Not Designated as Hedging Instrument [Member] | Noncurrent Assets- Other [Member]
Derivative [Line Items]
Derivative asset	0	0
Not Designated as Hedging Instrument [Member] | Accrued Expenses and Other Current Liabilities [Member]
Derivative [Line Items]
Derivative liability	(3)	$ (12)
Not Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative [Line Items]
Derivative liability	$ 0

Derivative Instruments (Movemen

Derivative Instruments (Movements out of OCI) (Details) - Foreign Exchange Contract [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative [Line Items]
Foreign currency transaction gains (losses)	$ (3)	$ (7)	$ 3
Cost of Sales [Member]
Derivative [Line Items]
Foreign currency transaction gains (losses)	19	1	0
Other Income (expense) [Member]
Derivative [Line Items]
Foreign currency transaction gains (losses)	$ (22)	$ (8)	$ 3

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2014	Apr. 30, 2014	Mar. 31, 2014
Small Bone Innovations [Member]
Business Acquisition [Line Items]
Purchase price paid, including debt	$ 365
Berchtold [Member]
Business Acquisition [Line Items]
Purchase price paid, including debt		$ 184
Patient Safety [Member]
Business Acquisition [Line Items]
Purchase price paid, including debt			$ 120

Acquisitions (Allocation Of The

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill	$ 4,136	$ 4,186	$ 3,844
Weighted average life of intangible assets	13 years	13 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Weighted average life of intangible assets	15 years	15 years
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Weighted average life of intangible assets	13 years	13 years
Other Acquisitions [Domain]
Business Acquisition [Line Items]
Purchase price paid	$ 138	$ 216
Contingent consideration	9	0
Total consideration	147	216
Cash	0	0
Inventory	10	5
Other assets	17	25
Liabilities	(5)	(29)
Goodwill	58	93
Assets acquired and liabilities assumed, net	$ 147	$ 216
Weighted average life of intangible assets	10 years	12 years
Other Acquisitions [Domain] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets	$ 12	$ 5
Other Acquisitions [Domain] | Trade Names [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets	2	0
Other Acquisitions [Domain] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets	51	115
Other Acquisitions [Domain] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets	2	0
Other Acquisitions [Domain] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets	$ 0	2
Small Bone Innovations [Member]
Business Acquisition [Line Items]
Purchase price paid		365
Contingent consideration		0
Total consideration		365
Cash		0
Inventory		23
Other assets		6
Liabilities		(2)
Goodwill		243
Assets acquired and liabilities assumed, net		$ 365
Weighted average life of intangible assets		12 years
Small Bone Innovations [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		$ 20
Small Bone Innovations [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		0
Small Bone Innovations [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		73
Small Bone Innovations [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		1
Small Bone Innovations [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		1
Berchtold [Member]
Business Acquisition [Line Items]
Purchase price paid		184
Contingent consideration		0
Total consideration		184
Cash		12
Inventory		22
Other assets		44
Liabilities		(45)
Goodwill		101
Assets acquired and liabilities assumed, net		$ 184
Weighted average life of intangible assets		8 years
Berchtold [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		$ 11
Berchtold [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		7
Berchtold [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		32
Berchtold [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		0
Berchtold [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		0
Patient Safety [Member]
Business Acquisition [Line Items]
Purchase price paid		120
Contingent consideration		0
Total consideration		120
Cash		0
Inventory		7
Other assets		19
Liabilities		(31)
Goodwill		66
Assets acquired and liabilities assumed, net		$ 120
Weighted average life of intangible assets		14 years
Patient Safety [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		$ 33
Patient Safety [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		0
Patient Safety [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		26
Patient Safety [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		0
Patient Safety [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Business combination, acquired intangible assets		$ 0

Goodwill and Other Intangible48

Goodwill and Other Intangibles Goodwill Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Goodwill, impairment loss	$ 0
Amortization of intangible assets	$ 210	$ 188	$ 138

Goodwill and Other Intangible49

Goodwill and Other Intangibles (Summary of the Company's Other Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	13 years	13 years
Gross Carrying Amount	$ 2,936	$ 2,986
Less Accumulated Amortization	1,142	968
Net Carrying Amount	$ 1,794	$ 2,018
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	13 years	13 years
Gross Carrying Amount	$ 1,597	$ 1,468
Less Accumulated Amortization	563	466
Net Carrying Amount	$ 1,034	$ 1,002
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	15 years	15 years
Gross Carrying Amount	$ 788	$ 801
Less Accumulated Amortization	290	239
Net Carrying Amount	$ 498	$ 562
Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	11 years	12 years
Gross Carrying Amount	$ 309	$ 293
Less Accumulated Amortization	191	175
Net Carrying Amount	$ 118	$ 118
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	10 years	14 years
Gross Carrying Amount	$ 109	$ 112
Less Accumulated Amortization	41	37
Net Carrying Amount	68	75
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	25	201
Less Accumulated Amortization	0	0
Net Carrying Amount	$ 25	$ 201
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	13 years	12 years
Gross Carrying Amount	$ 108	$ 111
Less Accumulated Amortization	57	51
Net Carrying Amount	$ 51	$ 60

Goodwill and Other Intangible50

Goodwill and Other Intangibles (Changes in Net Carrying Amount of Goodwill by Segment) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill, Beginning balance	$ 4,186	$ 3,844
Goodwill acquired	66	440
Foreign currency translation effects and other	(116)	(98)
Goodwill, Ending balance	4,136	4,186
Ortho
Goodwill [Roll Forward]
Goodwill, Beginning balance	2,386	2,227
Goodwill acquired	20	186
Foreign currency translation effects and other	(62)	(27)
Goodwill, Ending balance	2,344	2,386
MedSurg
Goodwill [Roll Forward]
Goodwill, Beginning balance	726	506
Goodwill acquired	46	231
Foreign currency translation effects and other	10	(11)
Goodwill, Ending balance	782	726
Neuro and Spine
Goodwill [Roll Forward]
Goodwill, Beginning balance	1,074	1,111
Goodwill acquired	0	23
Foreign currency translation effects and other	(64)	(60)
Goodwill, Ending balance	$ 1,010	$ 1,074

Goodwill and Other Intangible51

Goodwill and Other Intangibles (Estimated Amortization Expense) (Details) $ in Millions	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 202
2,017	183
2,018	181
2,019	165
2,020	$ 148

Contingencies and Commitments52

Contingencies and Commitments (Narrative) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2011patent	Dec. 31, 2015USD ($)patent	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2010patent
Payments for legal settlements		$ 54
Rent expense		101	$ 0	$ 0
Rejuvenate and ABG II Voluntary Recall [Member]
Estimate of possible loss		2,056
Litigation liability		232
Litigation liability net of insurance recoveries		$ 295
Electrical Network Communications, Hospital Beds [Member]
Patents allegedly infringed | patent	9	6
Patents found not infringed | patent		3
Minimum [Member] | Rejuvenate and ABG II Voluntary Recall [Member]
Estimate of possible loss		$ 1,824
Maximum [Member] | Rejuvenate and ABG II Voluntary Recall [Member]
Estimate of possible loss		2,416
Rejuvenate and ABG II Voluntary Recall [Member]
Litigation settlement, amount		$ 0
Zimmer Product Infringement [Member]
Litigation settlement, amount				$ 76
Number of patents allegedly infringed upon | patent					3

Contingencies and Commitments53

Contingencies and Commitments (Future Purchase Obligations and Minimum Lease Payments) (Details) $ in Millions	Dec. 31, 2015USD ($)
Purchase obligations
2,016	$ 802
2,017	125
2,018	62
2,019	55
2,020	2
Thereafter	67
Minimum lease payments
2,016	69
2,017	51
2,018	39
2,019	28
2,020	20
Thereafter	$ 56

Debt and Credit Facilities (Nar

Debt and Credit Facilities (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2015
Line of Credit Facility [Line Items]
Repayments of debt	$ 500
Maximum borrowing capacity				$ 1,250
Maturities of time deposits	397 days
Remaining borrowing capacity				1,236
Unamortized debt issuance expense				24
Debt instrument, fair value disclosure		$ 3,811		4,009
Interest expense, debt	$ 108	$ 113	$ 83
Senior Unsecured Notes 3.375% due 2025 [Member] [Member]
Line of Credit Facility [Line Items]
Long term debt				750
Stated interest rate	3.375%				3.375%
Commercial Paper [Member]
Line of Credit Facility [Line Items]
Commercial paper				$ 0

Debt and Credit Facilities (Mat

Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Total debt		$ 4,022		$ 3,973
Current maturities of debt		769		727
Total Long-term Debt		3,253		3,246
Senior Unsecured Notes 3.00% Due 2015 [Member]
Stated interest rate			3.00%
Maturity date	Jan. 15, 2015
Debt maturities in the next twelve months		0		500
Senior Unsecured Notes 2.00% due 2016 [Member]
Stated interest rate			2.00%
Maturity date	Sep. 30, 2016
Debt maturities in the next twelve months		750		750
Senior Unsecured Notes 1.30% due 2018 [Member]
Stated interest rate			1.30%
Maturity date	Apr. 1, 2018
Debt maturities in 2018		599		598
Senior Unsecured Notes 4.375% Due 2020 [Member]
Stated interest rate			4.375%
Maturity date	Jan. 15, 2020
Debt maturities after 2020		498		498
Senior Unsecured Notes 3.375% due 2024 [Member]
Stated interest rate			3.375%
Maturity date	May 15, 2024
Debt maturities after 2020		610		605
Senior Unsecured Notes 3.375% due 2025 [Member] [Member]
Stated interest rate	3.375%		3.375%
Maturity date	Nov. 1, 2025
Debt maturities after 2020		750		0
Senior Unsecured Notes 4.10% due 2043 [Member]
Stated interest rate			4.10%
Maturity date	Apr. 1, 2043
Debt maturities after 2020		395		395
Senior Unsecured Notes 4.375% due 2044 [Member]
Stated interest rate			4.375%
Maturity date	May 15, 2044
Debt maturities after 2020		398		398
Commercial Paper [Member]
Debt maturities after 2020		0		200
Other Debt [Member]
Debt maturities after 2020		$ 22		$ 29

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Capital Stock [Line Items]
Cash dividends declared, per share of common stock	$ 0.38	$ 0.345	$ 0.345	$ 0.345	$ 0.345	$ 0.305	$ 0.305	$ 0.305	$ 1.415	$ 1.26	$ 1.10
Shares repurchased (in shares)									7,400,000	1,300,000	4,800,000
Repurchase and retirement of shares of common stock									$ 700	$ 100	$ 317
Remaining shares authorized to be repurchased	$ 1,883								$ 1,883
Capital shares reserved for future issuance	15,000,000				19,000,000				15,000,000	19,000,000
Preferred stock, capital shares reserved for future issuance	500,000								500,000
Preferred stock, par per share	$ 1								$ 1
Options granted for period in number of years									10 years
Aggregate intrinsic value of options exercised									$ 98	$ 113	$ 97
Options exercised during period, exercise price range, lower range limit									$ 38.71
Options exercised during period, exercise price range, upper range limit									$ 102.27
Compensation cost not yet recognized	$ 79								$ 79
Compensation cost not yet recognized, period for recognized									1 year 7 months
Restricted Stock Units (RSUs) [Member]
Capital Stock [Line Items]
Compensation cost not yet recognized	53								$ 53
Compensation cost not yet recognized, period for recognized									12 months
Weighted average grant date fair value, granted (in dollars per share)									$ 88.47	$ 76.61
Shares vested during the period									$ 43
Performance Stock Units (PSUs) [Member]
Capital Stock [Line Items]
Compensation cost not yet recognized	$ 18								$ 18
Compensation cost not yet recognized, period for recognized									1 year 3 months
Weighted average grant date fair value, granted (in dollars per share)									$ 92.96
Employee Stock Purchase Plans [Member]
Capital Stock [Line Items]
Percentage of closing stock price under ESPP									95.00%
Shares issued under the ESPP									157,931	150,167

Capital Stock (Option Grant Ass

Capital Stock (Option Grant Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Capital Stock [Abstract]
Weighted-average fair value per share	$ 22.55	$ 15.80	$ 15.24
Risk-free interest rate	1.80%	2.10%	1.30%
Expected dividend yield	1.60%	1.80%	1.90%
Expected stock price volatility	25.50%	20.20%	27.90%
Expected option life	7 years 3 months	7 years 1 month	7 years 1 month

Capital Stock (Summary of Stock

Capital Stock (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Options outstanding at January 1 (in shares) | shares	15.2
Shares, Granted (in shares) | shares	2.4
Shares, Exercised (in shares) | shares	(2.4)
Shares, Cancelled (in shares) | shares	(0.3)
Shares, Options outstanding at December 31 (in shares) | shares	14.9
Shares, Exercisable at December 31 (in shares) | shares	8.3
Shares, Options expected to vest (in shares) | shares	6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding at January 1 (in dollars per share) | $ / shares	$ 59.97
Weighted average excercise price, Granted (in dollars per share) | $ / shares	93.06
Weighted average exercise price, Exercised (in dollars per share) | $ / shares	53.31
Weighted average exercise price, Cancelled (in dollars per share) | $ / shares	73.56
Weighted average exercise price, Options outstanding at December 31 (in dollars per share) | $ / shares	65.85
Weighted average exercise price, Exercisable at December 31 (in dollars per share) | $ / shares	56.67
Weighted average exercise price, Options expected to vest (in dollars per share) | $ / shares	$ 77.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average remaining contractual term, Options outstanding at December 31 (in years)	5 years 8 months 21 days
Weighted-average remaining contractual term, Exercisable at December 31 (in years)	3 years 10 months 21 days
Weighted-average remaining contractual term, Options expected to vest (in years)	7 years 10 months 21 days
Aggregate intrinsic value, Options outstanding at December 31 | $	$ 402.9
Aggregate intrinsic value, Exercisable at December 31 | $	302.2
Aggregate intrinsic value, Options expected to vest | $	$ 95.9

Capital Stock (Summary of RSU a

Capital Stock (Summary of RSU and PSU Activity) (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Nonvested at January 1 (in shares)	1.3
Shares, Granted (in shares)	0.6
Shares, Vested (in shares)	(0.7)
Shares, Cancelled (in shares)	(0.1)
Shares, Nonvested at December 31 (in shares)	1.1	1.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share)	$ 65.04
Weighted average grant date fair value, granted (in dollars per share)	88.47	$ 76.61
Weighted average grant date fair value, Vested (in dollars per share)	60.54
Weighted average grant date fair value, Cancelled (in dollars per share)	74.35
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share)	$ 79.71	$ 65.04
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Nonvested at January 1 (in shares)	0.3
Shares, Granted (in shares)	0.1
Shares, Vested (in shares)	0
Shares, Cancelled (in shares)	(0.1)
Shares, Nonvested at December 31 (in shares)	0.3	0.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share)	$ 66.18
Weighted average grant date fair value, granted (in dollars per share)	92.96
Weighted average grant date fair value, Vested (in dollars per share)	54.31
Weighted average grant date fair value, Cancelled (in dollars per share)	54.03
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share)	$ 79.02	$ 66.18

Income Taxes Income Taxes (Narr

Income Taxes Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Effective income tax, percent	17.10%	55.60%	17.00%
Interest expense and penalties included in other income (expense), net	$ 4	$ (8)	$ (12)
Net operating loss carryforward recognized	79	78	$ 16
Accrued interest and penalties	30	26
Operating loss carryforwards	152
Reinvestment of future remittances of undistributed earnings of foreign subsidiaries	7,166
Unrecognized tax benefits, interest on income tax expense	304	$ 307
Estimate of possible tax loss	55
UNITED STATES
Income Tax Contingency [Line Items]
Operating loss carryforwards	81
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	71
Operating loss carryforwards, valuation allowance	43
Tax credit carryforward, valuation allowance	$ 36

Income Taxes (Schedule of Earni

Income Taxes (Schedule of Earnings before Income Taxes) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States									$ 475	$ 355	$ 193
International									1,260	805	1,019
Earnings before income taxes	$ 612	$ 345	$ 401	$ 377	$ 461	$ 425	$ 167	$ 107	$ 1,735	$ 1,160	$ 1,212

Income Taxes (Schedule of Provi

Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current income tax expense
United States federal	$ 78	$ 213	$ 79
United States state and local	23	26	29
International	108	346	75
Total current income tax expense	209	585	183
Deferred income tax expense (benefit)
United States federal	2	9	(52)
United States state and local	8	(16)	(4)
International	77	67	79
Total deferred income tax expense (benefit)	87	60	23
Total income tax expense	$ 296	$ 645	$ 206

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States federal statutory rate	35.00%	35.00%	35.00%
United States state and local income taxes, less federal deduction	2.10%	2.20%	1.40%
International operations	(17.60%)	4.90%	(13.70%)
Tax related to repatriation of foreign earnings	(3.90%)	10.10%	0.00%
Other	1.50%	3.40%	(5.70%)
Effective income tax rate, total	17.10%	55.60%	17.00%

Income Taxes (Schedule of Diffe

Income Taxes (Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Deferred income tax assets:
Inventories	$ 513	$ 585
Product related liabilities	116	167
Other accrued expenses	206	226
Depreciation and amortization	4	44
State income taxes	43	68
Share-based compensation	79	90
Net operating loss carryforwards	47	123
Other	143	143
Total deferred income tax assets	1,151	1,446
Less valuation allowances	(47)	(42)
Net deferred income tax assets	1,104	1,404
Deferred income tax liabilities:
Depreciation and amortization	(586)	(666)
Undistributed earnings	50	132
Other	(26)	(54)
Total deferred income tax liabilities	(662)	(852)
Deferred Tax Assets, Net	442	552
Noncurrent assets—Other	477	594
Noncurrent liabilities—Other liabilities	$ (35)	$ (42)

Income Taxes (Schedule of Unres

Income Taxes (Schedule of Unresolved Income Tax Positions) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 315	$ 204
Increases related to current year income tax positions	21	133
Increases related to prior year income tax positions	3	23
Settlements and resolutions of income tax audits	(9)	(33)
Statute of limitations expirations	(6)	(1)
Foreign currency translation	(11)	(6)
Other	0	(5)
Balance at end of year	313	315
Current liabilities—Income taxes			$ 9	$ 3
Noncurrent liabilities—Other liabilities			304	312
Balance at end of year	$ 315	$ 204	$ 313	$ 315

Retirement Plans (Narrative) (D

Retirement Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Estimated net actuarial loss for the defined benefit pension plan	$ 7
Benefit obligation	529	$ 570	$ 456
Ending Accumulated benefit obligations	505	533
Fair value of plan assets	289	$ 310
Estimated future employer contributions in next fiscal year	$ 18

Retirement Plans (Schedule of D

Retirement Plans (Schedule of Defined Contribution Plan Disclosures) (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Plan expense	$ 148	$ 132	$ 132
Expense funded with Stryker common stock	20	18	16
Stryker common stock held by plan, amount	$ 203	$ 198	$ 150
Stryker common stock held by plan, shares	2.2	2.1	2
Stryker common stock held by plan, value as a percentage of total plan assets	11.00%	11.00%	9.00%

Retirement Plans (Schedule of F

Retirement Plans (Schedule of Funded Status and Components of the Amounts Recognized in the Consolidated Balance Sheets and in Accumulated Other Comprehensive Gain (Loss), Before the Effect of Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 289	$ 310
Benefit obligations	(529)	(570)	$ (456)
Funded status	(240)	(260)
Current liabilities—accrued compensation	(1)	(1)
Noncurrent liabilities—other liabilities	(239)	(259)
Unrecognized net actuarial loss	(142)	(180)
Service cost	(36)	(26)	(30)
Interest cost	(10)	(13)	(13)
Expected return on plan assets	11	10	10
Amortization of prior service cost and transition amount	1	1	1
Recognized actuarial loss	(13)	(7)	(8)
Net periodic benefit cost	(47)	(35)	(40)
Net actuarial gain (loss)	26	(88)	28
Recognized net actuarial loss	13	7	8
Prior service cost and transition amount	(1)	4	(1)
Total recognized in OCI	38	(77)	35
Total recognized in net periodic benefit cost and OCI	$ (9)	$ (112)	$ (5)
Defined Benefit Plan, Assumptions Used in Calculations [Abstract]
Discount rate	2.00%	3.20%	2.90%
Expected return on plan assets	4.00%	3.70%	3.70%
Expected return on plan assets	2.90%	2.90%	3.00%
Weighted-average discount rate used to determine projected benefit obligations	2.10%	2.00%	3.20%
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent
Defined Benefit Plan Disclosure [Line Items]
Unrecognized prior service cost	$ 13	$ 15
Unrecognized net actuarial loss	$ (155)	$ (195)

Retirement Plans (Schedule of C

Retirement Plans (Schedule of Change in Benefit Obligations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost	$ 47	$ 35	$ 40
Net actuarial gain (loss)	26	(88)	28
Recognized net actuarial loss	13	7	8
Prior service cost and transition amount	(1)	4	(1)
Total recognized in OCI	38	(77)	35
Total recognized in net periodic benefit cost and OCI	$ (9)	$ (112)	$ (5)
Discount rate	2.00%	3.20%	2.90%
Expected return on plan assets	4.00%	3.70%	3.70%
Expected return on plan assets	2.90%	2.90%	3.00%
Weighted-average discount rate used to determine projected benefit obligations	2.10%	2.00%	3.20%
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning Projected benefit obligations	$ 570	$ 456
Service cost	36	26	$ 30
Interest cost	(10)	(13)	(13)
Foreign exchange impact	(43)	(43)
Employee contributions	6	6
Recognized actuarial loss	(21)	134
Plan amendments	0	(5)
Acquisitions	0	5
Benefits paid	(29)	(22)
Ending Projected benefit obligations	529	570	456
Expected return on plan assets	11	10	10
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(1)	(1)	(1)
Recognized actuarial loss	(13)	(7)	$ (8)
Ending Accumulated benefit obligations	$ 505	$ 533

Retirement Plans (Change in Pla

Retirement Plans (Change in Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Beginning Fair value of plan assets	$ 310	$ 281
Actual return	2	46
Employer contributions	16	18
Employee contributions	6	6
Foreign exchange impact	(18)	(24)
Acquisition	0	3
Benefits paid	(27)	(20)
Ending Fair value of plan assets	$ 289	$ 310

Retirement Plans (Schedule of T

Retirement Plans (Schedule of Target and Actual Allocation of Plan Assets) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	100.00%
Actual plan asset allocations	100.00%	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	29.00%
Actual plan asset allocations	31.00%	30.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	50.00%
Actual plan asset allocations	48.00%	48.00%
Other Long-term Investments
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	21.00%
Actual plan asset allocations	21.00%	22.00%

Retirement Plans (Schedule of V

Retirement Plans (Schedule of Valuation of the Company's Pension Plan Assets by Pricing Categories) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 289	$ 310
(Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	227	243
(Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31	34
(Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31	33	$ 22
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	6
Cash and cash equivalents | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	6
Cash and cash equivalents | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash and cash equivalents | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	89	125
Equity securities | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	67	99
Equity securities | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22	26
Equity securities | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	135	121
Corporate debt securities | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	135	121
Corporate debt securities | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Corporate debt securities | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	59	58
Other | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	19	17
Other | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	8
Other | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 31	$ 33

Retirement Plans (Rollforward o

Retirement Plans (Rollforward of Level 3 Pension Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Balance on January 1	$ 310
Balance on December 31	289	$ 310
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Balance on January 1	33	22
Actual return on plan assets held at the reporting date	(2)	11
Balance on December 31	$ 31	$ 33

Retirement Plans (Expected Bene

Retirement Plans (Expected Benefit Payments) (Details) $ in Millions	Dec. 31, 2015USD ($)
Compensation and Retirement Disclosure [Abstract]
2,016	$ 14
2,017	14
2,018	13
2,019	14
2,020	13
2021-2025	$ 77

Segment and Geographic Data (Sa

Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments | segment									3
Net sales	$ 2,715	$ 2,420	$ 2,432	$ 2,379	$ 2,618	$ 2,389	$ 2,363	$ 2,305	$ 9,946	$ 9,675	$ 9,021
Depreciation and amortization									590	586	511
Segment net earnings (loss)									1,861	1,246	1,256
Intangible asset amortization									(210)	(188)	(138)
Net earnings	$ 522	$ 301	$ 392	$ 224	$ 260	$ 57	$ 128	$ 70	1,439	515	1,006
Operating Segments [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization									539	566	492
Income (Loss) from Continuing Operations Attributable to Parent									2,783	2,736	2,585
Corporate [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization									51	20	19
Segment Reconciling Items
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations Attributable to Parent									(302)	(322)	(314)
Acquisition & integration-related charges									(35)	(102)	(98)
Intangible asset amortization									(210)	(188)	(138)
Restructuring related charges									(132)	(117)	(63)
Less Rejuvenate and related charges									(296)	(761)	(622)
Regulatory and legal matters									53	0	(69)
Less donation									0	0	(25)
Net earnings									1,861	1,246	1,256
Ortho | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net sales									4,223	4,153	3,949
Depreciation and amortization									290	319	273
Segment net earnings (loss)									1,487	1,410	1,353
MedSurg | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net sales									3,895	3,781	3,414
Depreciation and amortization									117	113	84
Segment net earnings (loss)									822	850	802
Neuro and Spine | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net sales									1,828	1,741	1,658
Depreciation and amortization									132	134	135
Segment net earnings (loss)									$ 474	$ 476	$ 430

Segment and Geographic Data Seg

Segment and Geographic Data Segment and Geographic Data (Segment Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Assets	$ 16,247	$ 17,279	$ 15,399
Capital Expenditures During Period	270	233	195
Operating Segments [Member]
Segment Reporting Information [Line Items]
Assets	15,394	17,598	15,306
Capital Expenditures During Period	212	177	164
Operating Segments [Member] | Ortho
Segment Reporting Information [Line Items]
Assets	6,149	8,357	7,756
Capital Expenditures During Period	95	80	89
Operating Segments [Member] | MedSurg
Segment Reporting Information [Line Items]
Assets	5,341	5,557	4,533
Capital Expenditures During Period	89	77	59
Operating Segments [Member] | Neuro and Spine
Segment Reporting Information [Line Items]
Assets	3,904	3,684	3,017
Capital Expenditures During Period	28	20	16
Corporate [Member]
Segment Reporting Information [Line Items]
Assets	853	(319)	93
Capital Expenditures During Period	$ 58	$ 56	$ 31

Segment and Geographic Data (Ge

Segment and Geographic Data (Geographic Information on Net Sales and Long-Lived Assets) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales	$ 2,715	$ 2,420	$ 2,432	$ 2,379	$ 2,618	$ 2,389	$ 2,363	$ 2,305	$ 9,946	$ 9,675	$ 9,021
Net Property, Plant & Equipment	1,199				1,098				1,199	1,098
United States
Segment Reporting Information [Line Items]
Net sales									7,116	6,558	5,984
Net Property, Plant & Equipment	626				539				626	539
Europe, Middle East, and Africa
Segment Reporting Information [Line Items]
Net sales									1,267	1,371	1,316
Net Property, Plant & Equipment	432				417				432	417
Asia Pacific
Segment Reporting Information [Line Items]
Net sales									1,251	1,368	1,319
Net Property, Plant & Equipment	116				119				116	119
Other foreign countries
Segment Reporting Information [Line Items]
Net sales									312	378	$ 402
Net Property, Plant & Equipment	$ 25				$ 23				$ 25	$ 23

Summary of Quarterly Data (Un78

Summary of Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Data [Abstract]
Net sales	$ 2,715	$ 2,420	$ 2,432	$ 2,379	$ 2,618	$ 2,389	$ 2,363	$ 2,305	$ 9,946	$ 9,675	$ 9,021
Gross profit	1,820	1,624	1,605	1,553	1,718	1,560	1,548	1,529	6,602	6,356	6,019
Earnings before income taxes	612	345	401	377	461	425	167	107	1,735	1,160	1,212
Net earnings	$ 522	$ 301	$ 392	$ 224	$ 260	$ 57	$ 128	$ 70	$ 1,439	$ 515	$ 1,006
Basic net earnings per share of common stock (in dollars per share)	$ 1.39	$ 0.80	$ 1.04	$ 0.59	$ 0.68	$ 0.16	$ 0.34	$ 0.19	$ 3.82	$ 1.36	$ 2.66
Diluted net earnings per share of common stock (in dollars per share)	1.38	0.79	1.03	0.58	0.67	0.16	0.33	0.18	3.78	1.34	2.63
Market Price Of Common Stock, High	100.51	105.34	97.94	96.18	98.24	85.91	86.93	83.86
Market Price Of Common Stock, Low	90.30	91.73	90.19	89.81	77.87	78.91	75.78	74.02
Dividends declared per share of common stock	$ 0.38	$ 0.345	$ 0.345	$ 0.345	$ 0.345	$ 0.305	$ 0.305	$ 0.305	$ 1.415	$ 1.26	$ 1.10